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ABSTRACT 
Down syndrome (DS) is a genetic disorder that results from triplication of human chromosome 21 
(Hsa21) and occurs in around 1 in 1000 live births. All individuals with DS present with skeletal 
abnormalities typified by craniofacial features, short stature and low bone mineral density (BMD). 
Differences between males and females with DS suggest a sexual dimorphism in how trisomy 
affects skeletal deficits associated with trisomy 21 (Ts21). Previous investigations of skeletal 
abnormalities in DS have varied methodology, sample sizes and ages making the underlying 
causes of deficits uncertain. Mouse models of DS were used to characterize skeletal abnormalities, 
but the genetic and developmental origin remain unidentified. Over-expression Dyrk1a, found on 
Hsa21 and mouse chromosome 16 (Mmu16) has been linked to cognitive deficits and skeletal 
deficiencies. Dp1Tyb mice contain three copies of all of the genes on Mmu16 that are homologous 
to Hsa21, males and females are fertile, and therefore are an excellent model to test the hypothesis 
that gene dosage influences the sexual dimorphism of bone abnormalities in DS. Dp1Tyb at 6 
weeks 16 weeks showed distinctive abnormalities in BMD, trabecular architecture, and reduced 
bone strength over time that occur generally through an interaction between sex and genotype. 
Increased gene dosage and sexual dimorphism in Dp1Tyb mice revealed distinct phenotypes in 
bone formation and resorption. To assess how Dyrk1a influences the activity and function of 
osteoblasts Ts65Dn female trisomic mice, female mice with a floxed Dyrk1a gene (Ts65Dn, 
Dyrk1afl/+) were be bred to Osx1-GFP::Cre+ mice to generate Ts65Dn animals with a reduced 
copy of Dyrk1a in mature osteoblast cells. Female Ts65Dn,Dyrk1a+/+/+ and Ts65Dn,Dyrk1a+/+/-
displayed significant defects in both trabecular architecture and cortical geometry. Ultimate force 
was reduced in trisomic animals, suggesting whole bone and tissue level properties are not 
adversely affected by trisomy. Reduction of Dyrk1a functional copy number in female mice did 
not improve skeletal deficits in an otherwise trisomic animal. Dyrk1a may not alter osteoblast 
cellular activity in an autonomous manner in trisomic female mice. These data establish sex, gene 
dosage, skeletal site and age as important factors in skeletal development of the skeleton in DS 
mice, potentially paving the way for identification of the causal dosage-sensitive genes in both 
male and female animals.   
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 INTRODUCTION 
1.1 Down Syndrome 
Down syndrome (DS) is the most common genetic cause of intellectual disability and the 
result of the triplication of human chromosome 21 (Hsa21) (Turpin & Lejeune, 1965). Most cases 
of Trisomy 21 (Ts21) results from non-disjunction of Hsa21 during meiosis as a freely segregating 
chromosome or a Robertsonian translocation (Epstein, 2014). Additionally, DS can result from 
partial trisomies where a portion of Hsa21 genes are triplicated or mosaicism with trisomy of 
Hsa21 in some cells and two copies of Hsa21 in other cells. Phenotypes associated with partial 
trisomies or mosaics vary in severity depending on the number and distribution of trisomic genes 
and cells respectively. The only identified risk of DS is associated with the age of the mother by 
analyzing the rates of non-disjunction during gamete formation (Hernandez & Fisher, 1996). Ts21 
affects ~1/800 to 1/1000 live births and results in distinctive craniofacial features and skeletal 
deficits, including short stature in all individuals with DS (Baptista, Varela, & Sardinha, 2005; 
Center, Beange, & McElduff, 1998; Gonzalez-Aguero, Vicente-Rodriguez, Moreno, & Casajus, 
2011; Mai et al., 2019; McKelvey et al., 2013; Parker et al., 2010). Phenotypic variability and 
severity in individuals with DS are poorly understood and it is necessary to investigate the 
molecular and genetic factors that contribute to the skeletal phenotype in individuals with DS.  
Alterations in skeletal features in individuals with DS begin prenatally and continue 
postnatally; adolescents exhibit low bone accrual during puberty, and adults have documented 
bone loss (Angelopoulou, Souftas, Sakadamis, & Mandroukas, 1999; Baptista et al., 2005; 
Gonzalez-Aguero et al., 2011). Fetuses with Ts21 are often characterized ultrasonically with a 
short femur and humerus, but these soft markers are not diagnostic (Bromley, Lieberman, Shipp, 
& Benacerraf, 2002a, 2002b; Longo, DeFigueiredo, Cicero, Sacchini, & Nicolaides, 2004; Nyberg 
et al., 2001). At birth, individuals with DS have a  shorter stature than the general population 
(Cronk et al., 1988; Myrelid, Gustafsson, Ollars, & Anneren, 2002) and on average, this reduced 
height continues throughout life (Baptista et al., 2005). The short stature caused by Ts21 is related 
to a delay in the development of the secondary centers of ossification and final peak height reached 
around the age of 15 (Angelopoulou et al., 1999; de Moraes, Tanaka, de Moraes, Filho, & de Melo 
Castilho, 2008). Peak bone mass is reached ~5-10 years earlier than normal and is lower in 
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individuals with DS as compared to the general population (Costa et al., 2018). This predisposition 
to weaker and shorter bones in people with Ts21, through attenuated bone accrual or altered 
organization, may be exacerbated due to hypotonia, hormonal and nutritional deficits, growth 
retardation, low muscle strength and reduced physical activity (Carfi et al., 2017; Esbensen, 2010; 
Hawli, Nasrallah, & El-Hajj Fuleihan, 2009).  
1.1.1 History of Down syndrome 
Around the mid-19th century, DS was first mentioned in Jean-Etienne-Dominique-
Esquirol’s first handbook of psychiatry entitled “Des maladies mentales considerées sous les 
rapports medical, hygienique et medico-legal (Mental Disease: medical, health/hygiene and 
medical-legal considerations” (Esquirol & Hunt, 1845; Patterson & Costa, 2005). “Idiocy” was a 
section in his handbook that characterized ‘mental deficiency or retardation’, accompanied by 
physical characteristics including patients with oblique eye fissures, epicanthic eye-folds, a flat 
nasal bridge, short stocky nature, malformed limbs and protruding tongue (Esquirol & Hunt, 1845; 
Roubertoux & Kerdelhue, 2006). Edouard Seguin added to the symptomatological description of 
these patients, around 8 years later, by adding small nose, open mouth and the morphology of the 
tongue and susceptibility of lung infections (Roubertoux & Kerdelhue, 2006; Seguin, 1866). He 
believed that these “good kids” had the ability to communicate and gain some basic knowledge 
despite “profound idiocy” (Seguin, 1866). It  also has been suggested that advancement in 
understanding of the cause of DS parallels the history of human genetics (Patterson & Costa, 2005). 
In 1866, at the mental hospital where John Langdon Down was working, he separated his patients 
into ethnic groups, and stated “A very large number of congenital idiots are typical Mongols” 
(Roubertoux & Kerdelhue, 2006). This description referred to Langdon’s perspective that patients 
with DS appeared to have similar facial features as individuals from Mongolia. He added to the 
phenotype of DS by noting a flat broad face, scanty hair, small nose, and long, thick protruding 
roughened tongue (Down, 1995). He stated they had the ability to speak, although their speech 
was inarticulate, also they had a great sense of humor. With training individuals with DS could 
improve their speech, motor functioning, physical and mental capabilities, and possessing a 
reduced life expectancy (Roubertoux & Kerdelhue, 2006).  
The term “Mongol” or “mongolism” was used to describe features of individuals with DS 
and was used commonly by the 19th century and until the 1960s. (Patterson & Costa, 2005; 
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Roubertoux & Kerdelhue, 2006). It was viewed as a derogatory term used to describe DS and 
thought to be a non-scientific etiology. Individuals petitioned the World Health Organization 
(WHO) to formally request the term ‘Mongol’ and ‘mongolism’ be eschewed  and  was established 
by the National Institute of Health (NIH) in 1975 (Howard-Jones, 1979; Patterson & Costa, 2005; 
Roubertoux & Kerdelhue, 2006). Individuals in the scientific community suggested the term be 
discarded and replaced with either “trisomy 21 anomaly” or “Down’s syndrome” which became 
common parlance in the 1970s (Howard-Jones, 1979; Patterson & Costa, 2005; Roubertoux & 
Kerdelhue, 2006).  
During the early to mid-20th century, several scientists discovered chromosomes and their 
behavior during cell division. Thomas H. Morgan published several studies that provided almost 
conclusive evidence that genes are located on chromosomes (Patterson & Costa, 2005). Early 
investigations into number of chromosomes yielded evidence that humans had around 46 
chromosomes (Patterson & Costa, 2005) and that lead Charles Davenport to consider that the cause 
of intellectual disabilities was a chromosomal irregularity. Following the discovery of the correct 
number of human chromosomes Jerome Lejeune showed that DS was the result of triplication of 
Hsa21 (Patterson & Costa, 2005).  
1.1.2  Genotype and Phenotype Relationship 
DS is the most compatible genetic chromosomal anomaly with human survival past term 
(Olson et al., 2007). DS phenotypes are highly variable and have considerable genetic complexity, 
thus making it difficult to understand mechanisms related to developmental disruption by Ts21 
(Olson et al., 2007). Majority of the incidence of DS results from Ts21 and some from 
translocations of portions of Hsa21 on other chromosomes (S .L. Deitz, Blazek, Solzak, & Roper, 
2011; Epstein, 2014). Also, some individuals with DS phenotypes have Ts21 in only a portion of 
their cells (mosaicism) while other cells have the normal number of chromosomes (S .L. Deitz et 
al., 2011; Epstein, 2014). Cellular and genetic composition in individuals with DS contribute to 
differences in variation and severity of observed phenotypes. It has been hypothesized that specific 
trisomic genes or chromosomal regions may cause or alter DS phenotypes due to genotype-
phenotype correlations (S .L. Deitz et al., 2011). It is still unclear how genetic mechanisms of Ts21 
result in various phenotypes seen in DS, yet it is unlikely that a single mechanism is responsible 
for the etiology of all Ts21 phenotypes. Identification of the genetic mechanisms affecting DS 
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phenotypes that are influenced by differential spatiotemporal gene expression in various tissues 
can lead to therapeutics that could correct distinct DS phenotypes (Conti et al., 2007; Lintas et al., 
2010; Lyle et al., 2004; Moldrich et al., 2007).  
The most common techniques used in the investigation into a relationship between 
genotype-phenotype correlations included mapping of partial trisomies, mouse models, studying 
gene expression in tissues or cells, and transgenic mice overexpressing one gene. From these 
investigations, the distal arm of Hsa21 was thought to be sufficient to cause phenotypes associated 
with DS (Patterson & Costa, 2005). It was hypothesized that specific regions on Hsa21 resulted in 
specific phenotypes and that the extent of the trisomic region relates to the variation and severity 
of traits associated with DS (Delabar et al., 1993; Korenberg et al., 1994; McCormick et al., 1989; 
Niebuhr, 1974).  
Gene Dosage Hypothesis 
The central hypothesis in DS research is that gene expression is elevated by 50% or 1.5 
fold as a result from increased gene dosage which alters development of individuals with DS 
(Amano et al., 2004; K. Gardiner, 2004; Kahlem et al., 2004). Based on the assumption that a gene 
present in three copies results in elevated expression, two principal hypotheses of how Ts21 causes 
DS were proposed. The first hypothesis of the genotype-phenotype relationship was that genomic 
imbalance caused DS phenotypes (Patterson & Costa, 2005). The genetic dosage imbalance 
hypothesis suggests that increased copy number or dosage on Hsa21 genes would lead to increased 
gene expression or protein (Antonarakis, Lyle, Dermitzakis, Reymond, & Deutsch, 2004; Epstein, 
2014). Overexpression of dosage sensitive genes would lead to DS phenotypes and specific genes 
or subsets of genes are sufficient cause specific phenotypes (S .L. Deitz et al., 2011; Patterson, 
2007). Further investigations have highlighted that changes in gene expression may be specific to 
a particular tissue at a precise developmental or mature stage (S .L. Deitz et al., 2011).  
Amplified Genetic Instability  
The second hypothesis is amplified developmental instability that refers to the phenomenon 
observed when an increased dosage of a number of trisomic genes leads to genetic imbalance that 
impacts the expression and regulation of many genes throughout the genome (S .L. Deitz et al., 
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2011; Pritchard & Kola, 1999). The presence of an extra chromosome is assumed to result in the 
disruption of genetic homeostasis throughout the genome, possibly affecting various signaling 
pathways associated with phenotypes observed in DS (S .L. Deitz et al., 2011; Patterson, 2009). 
This hypothesis is an attempt to explain the observations of DS traits that are similarly seen in 
other aneuploid states and normosomic people. Therefore, it has been hypothesized that changes 
in global genomic expression caused by Ts21 can lead to DS phenotypes (S .L. Deitz et al., 2011). 
The severity and incidence of phenotypes associated with DS is thought to be dependent on the 
number of trisomic genes, and that phenotypes are associated to changes in genetic expression in 
the entire chromosomal domain (K. J. Gardiner, 2010).  
Down Syndrome Critical Region 
Studies of individuals with chromosomal rearrangements that resulted in triplication of a 
subset of Hsa21 genes or segmental trisomy were used to identify similarities in phenotypes with 
individuals with DS (Olson et al., 2007; Patterson & Costa, 2005; Roubertoux & Kerdelhue, 2006). 
Correspondence of a region of overlap between patients with DS that possessed the same 
phenotypes led to a concept that a critical chromosomal region of dosage sensitive genes was 
responsible for various phenotypes associated with DS (Delabar et al., 1993; Korbel et al., 2009; 
Olson et al., 2007). The Down syndrome critical region (DSCR) contained approximately 33 genes 
found on Hsa21 (Olson, Richtsmeier, Leszl, & Reeves, 2004). The DSCR included Dyrk1a and 
was thought to contribute to the most severe features of DS (Korbel et al., 2009; Korenberg et al., 
1994; Richtsmeier, Zumwalt, Carlson, Epstein, & Reeves, 2002). The hypothesis suggested that 
the genes in this region were sufficient to engender these phenotypes. Further investigations 
concluded that genes located within the DSCR were insufficient but necessary to produce 
phenotypes associated with DS (S. L. Deitz & Roper, 2011; Olson et al., 2007). However, specific 
regions or genes may contribute to the incidence and severity of specific DS phenotypes (Korbel 
et al., 2009; Lyle et al., 2009), leading to the idea that increased gene dosage could generate 
susceptibility regions that influence particular phenotypes through interactions between trisomic 
and non-trisomic genes during development in individuals with DS (Lyle et al., 2009).  It is 
important to define the etiology of phenotypes associated with DS, such as skeletal deficits, to 
identify possible mechanisms related to the development of phenotypes and possible therapeutic 
value. 
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1.1.3 Skeletal Deficits Associated with DS 
The increased average expected lifespan of individuals with DS (~60 years) is mostly 
attributable to societal acceptance and therapeutic advancements (Baird & Sadovnick, 1989; 
Bittles & Glasson, 2004; Weijerman & de Winter, 2010), but individuals with DS are thus at 
increased risk for low bone mineral density (BMD) and fractures. Skeletal deficiencies and lack 
of bone mass accrual during development predispose people with Ts21 to fragility fractures, and 
at later ages, osteoporosis (Baptista et al., 2005; Barnhart & Connolly, 2007; Center et al., 1998; 
Hawli et al., 2009).  Bones are significantly weaker in adults with DS as compared to others with 
intellectual disabilities or normally developing individuals (Geijer, Stanish, Draheim, & Dengel, 
2014; Rosello, Torres, Boronat, Llobet, & Puerto, 2004; van Allen, Fung, & Jurenka, 1999); all 
people with DS are at risk for osteoporosis and osteopenia (de Graaf, Buckley, & Skotko, 2017; 
de Moraes et al., 2008; Keeling, Hansen, & Kjaer, 1997); and a high percentage of older 
individuals with DS have suffered fractures (van Allen et al., 1999). Spine trauma and femur 
fractures in this population are increasingly significant causes for morbidity (Chaney & Eyman, 
2000; McKelvey et al., 2013), and the rate of falls is increased in persons with cognitive 
impairment (Baptista et al., 2005). Although the risk for osteoporosis is higher in adults with 
intellectual disabilities, the overall bone density screening rates and reports of fracture incidence 
are lower in these same individuals (Dreyfus, Lauer, & Wilkinson, 2014; LaCombe & Roper, 
2020). Individuals with DS exhibit many hallmarks associated with osteoporosis including a lower 
BMD, altered geometry, and reduced overall strength. These skeletal deficits found in DS are not 
only age- and sex-dependent, like normally developing individuals, but are also influenced by 
having three copies of the genes on Hsa21. Because of the known skeletal abnormalities in all 
people with DS and the increasing age in the same population, there is a critical need to address 
the etiology of these skeletal abnormalities.  
Some differences in bone properties between males and females with Ts21 have been 
observed, but low sample sizes, variety of analysis methods, wide array of ages, different skeletal 
measurement sites, and the etiology of sexual dimorphism remains unclear. Adolescent females 
with DS are hypothesized to acquire BMD at a lower rate compared to adolescent males with DS 
(Baptista et al., 2005; Gonzalez-Aguero et al., 2011). BMD is decreased in the lumbar spine of 12-
16 year old males and females (analyzed together) with DS compared to age matched adolescents 
(Kao, Chen, Wang, & Yeh, 1992). Twenty adolescents with DS (males and females analyzed 
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together, average age of ~15 years) compared to 20 males and females without DS (average age 
of ~13 years) showed a lower BMD in lumbar spine, hip, and whole body (Matute-Llorente, 
Gonzalez-Aguero, Gomez-Cabello, Vicente-Rodriguez, & Casajus, 2013). However, no 
differences were seen in femur BMD between males and females with Ts21 in a study of 12 males 
and 14 females with DS (average age ~17 and 16 years, respectively) (Matute-Llorente et al., 2017). 
When the lumbar vertebrate of males and females (average age ~25 years) with and without DS 
were analyzed, males with DS as compared to controls had 25% lower BMD and females with DS 
had 14% lower BMD (Angelopoulou et al., 1999). Both males (average age ~26 years) and females 
(average age ~24 years) showed a lower BMD than control groups of males and females, and BMD 
was 9% lower in males with DS as compared to females with DS (Angelopoulou et al., 1999). 
Males with Ts21 have been reported to have greater BMD and bone area in the upper and lower 
limbs than females with DS (Baptista et al., 2005). Additionally, osteopenia has been reported to 
occur earlier in males with DS (McKelvey et al., 2013) and unlike the most common forms of 
osteoporosis where 80% of the affected individuals are women, osteoporosis affects both men and 
women with Ts21. To determine BMD, most studies use Z-scores (healthy subjects of same age 
and sex) (Angelopoulou et al., 2000; Costa et al., 2017) and others use T-scores (healthy subjects 
between 25 and 30 years of the same sex and race at peak bone mass) (Baptista et al., 2005; Carfi 
et al., 2017; Kao et al., 1992). Differences in calculations of BMD using T- or Z-scores to 
determine a low bone mass or osteoporosis add to the variation and bias in individuals with DS. 
Recent publications detail skeletal deficiencies across life stages in males and females with 
DS in larger sample sizes and compared to normal developing populations. When femoral neck 
and lumbar spine was measured in 234 males and females with Ts21 ages 20-69 and compared 
with a reference control sample, both males and females with DS showed lower lumbar spine BMD 
in every decade of life measured (Carfi et al., 2017). Males with DS had reduced femoral neck 
BMD beginning in their 20s but females with DS did not show reduced femoral neck BMD until 
their 40s. Both males and females with Ts21 (237 individuals with DS aged 15-64) had reduced 
lumbar spine and femoral neck BMD from their 20s to their 60s as compared to a reference 
population (Costa et al., 2018). When 128 adults with DS (ages 18-54) were compared to 723 age-
matched adults without DS and other intellectual disabilities, lumbar spine BMD in men was 
relatively stable in early to mid-adulthood, and bone mineral accrual was later in women than men 
with DS (Tang et al., 2019). Women with DS also saw a rapid loss of bone mass after age 40. Both 
 
 
20 
men and women with DS had higher rates of osteopenia and osteoporosis than a reference 
population. Taken together, these data indicate different skeletal deficits seen in males and females 
with DS, but they are complex in their nature, and not well defined in relation to age, skeletal site, 
and fracture risk.  
1.2 Mouse Models of DS 
Mouse models of DS. Human chromosome 21 is shown at the top of the figure, with mouse 
genome orthologous regions found Mmu16 (orange), Mmu10 (red), and Mmu17 (light green). A 
few known Hsa21 genes are listed below each chromosome. Ts65Dn is shown in brown and 
Dp1Tyb is shown in dark green.  
 
1.2.1 Ts65Dn 
Mouse models recapitulate the genetic (trisomy) and phenotypic (DS-associated traits) 
features attributed to Ts21 and are utilized to understand skeletal phenotypes associated with DS. 
The Ts(1716)65Dn mouse (Ts65Dn), the most widely used and well-characterized mouse model of 
DS, has conserved homology between Hsa21 and Mmu16 (Gupta, Dhanasekaran, & Gardiner, 
2016; Roper & Reeves, 2006; Sturgeon & Gardiner, 2011). Ts65Dn displays a segmental trisomy 
of the distal end of Mmu16 that triplicates about half of the gene orthologs found on Hsa21 (Reeves 
et al., 1995; Sturgeon & Gardiner, 2011). Additionally, Ts65Dn mice contain three copies of ~35 
protein coding genes from mouse chromosome 17 (Mmu17) that are orthologous to Hsa6 (Duchon 
et al., 2011; Gupta et al., 2016; Reinholdt et al., 2011). Ts65Dn mice exhibit several phenotypes 
seen in humans with DS including cognitive impairment, craniofacial deficits, and cardiovascular 
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anomalies (Baxter, Moran, Richtsmeier, Troncoso, & Reeves, 2000; Blazek, Gaddy, Meyer, Roper, 
& Li, 2011; Holtzman et al., 1996; Insausti et al., 1998; Richtsmeier, Baxter, & Reeves, 2000; 
Williams, Mjaatvedt, & Moore, 2008). Ts65Dn mice display a reduction in BMD, osteoporotic-
like structural deficiencies in the mechanical strength, cortical and trabecular bone of the femur in 
adolescent and adult mice (Blazek et al., 2011; Fowler et al., 2012; Parsons, Ryan, Reeves, & 
Richtsmeier, 2007).  
Skeletal Deficits Associated with Ts65Dn Mice 
Adult Ts65Dn male mice show structural and biomechanical skeletal deficits (Blazek et al., 
2011; Fowler et al., 2012; Parsons et al., 2007). Ts65Dn male mice exhibit significantly less BMD, 
BMC and bone area in both femur and skull at 6 and 16 weeks when compared to euploid 
littermates (Blazek et al., 2011). A significantly lower percentage of bone volume (bone 
volume/tissue volume--BV/TV) was observed in trabecular bone of trisomic mice as compared to 
wild-type littermates. Ts65Dn male mice also exhibited significantly lower trabecular number and 
significantly higher trabecular separation at both time points. These changes indicate that trisomy 
causes altered trabecular microstructure that is more poorly organized, similar to that observed in 
osteoporotic bone. Cortical bone analysis of 6-week-old male mice showed significantly lower 
cross-sectional area and mean total periosteal perimeter in Ts65Dn as compared to control 
littermate mice. Mechanical parameters that assess bone strength were also significantly lower in 
male Ts65Dn mice as compared to euploid littermates, as seen with a reduced ultimate load and 
stiffness in Ts65Dn mice at 6 and 16 weeks of age. A significant increase in osteoclast surface and 
osteoclast number was observed in 6-week-old Ts65Dn compared to wild-type male mice (Blazek, 
Abeysekera, Li, & Roper, 2015). Overall, studies in mice and humans imply that trisomy causes 
developmental bone abnormalities, compromised bone strength, and early onset osteoporosis due 
to a combination of altered developmental, homeostatic and resorptive bone mechanisms (Blazek, 
Abeysekera, et al., 2015; Blazek et al., 2011; Fowler et al., 2012).  
Although skeletal differences between normal and trisomic bone have been established 
using DS mouse models, little has been done to examine the skeletal structure, mechanics and 
cellular composition affected by trisomy and depending on sex, mostly because female Ts65Dn 
mice are reserved for colony maintenance. Contribution of the additional genes from Mmu17 
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found in trisomic Ts65Dn mice to skeletal phenotypes is unknown and requires additional research 
(Duchon et al., 2011; Gupta et al., 2016; Reinholdt et al., 2011).  
1.3 Ts1Rhr 
The occurrence of decreased BMD seen in individuals with DS has been established, 
however the etiology remains unknown (Olson & Mohan, 2011). It is unclear if specific genes are 
the causative means of reduced BMD therefore, the analysis of the skeletal phenotype in mouse 
models of DS can help identify mechanisms that contribute to skeletal anomalies. Ts1Rhr mice 
contained 33 orthologous Hsa21 genes found within the DSCR including Dyrk1a (Olson et al., 
2004) and were generated to determine if genes found in the DSCR were sufficient to produce 
phenotypes seen in DS and Ts65Dn (Olson et al., 2007). Ts1Rhr were used to investigate the 
contribution of DSCR genes in the development of skeletal abnormalities of DS (Olson & Mohan, 
2011).  No differences in BMD were seen at 3 or 16 weeks in male or female Ts1Rhr mice perhaps 
due to the low number of genes at dosage imbalance, minimal impact of genes in three copies in 
this model on skeletal structure, ages sampled or the methodology used, including just examining 
BMD in these animals (Olson & Mohan, 2011).  The use of additional skeletal analyses could 
reveal deficits in femoral architecture or cortical geometry that were not investigated in previous 
studies and elucidate novel genetic contributions associated with skeletal abnormalities seen in DS. 
1.3.1 Dp1Tyb 
C57BL/6J.129P2-Dp(16Lipi-Zbtb21)1TybEmcf/Nimr (Dp1Tyb) mice have a duplication on 
Mmu16 Lipi to Zbtb21 spanning 23 Mb with 148 coding genes and contain three copies of all of 
the genes on Mmu16 that are orthologous to Hsa21 (Lana-Elola et al., 2016). Lana-Elola et al. 
investigated which genes on Hsa21cause cardiovascular defects associated with DS and how they 
arise. To identify dosage-sensitive critical regions and candidate genes, they generated Dp1Tyb 
mice. Then they produced 7 additional mouse strains that were used to identify the genetic basis 
of DS phenotypes and narrowed the potential genes to a list of 39 genes, and then showed at least 
2 genes were required in three copies to cause heart defects (Lana-Elola et al., 2016). Also, both 
male and female Dp1Tyb mice are fertile which facilitates examination of skeletal features for 
both sexes in this mouse model. It has been hypothesized that increased dosage of one or more 
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genes on Hsa21 results in DS phenotypes (Delabar et al., 1993; Korenberg et al., 1994; Lyle et al., 
2009). Previous mouse models have been used to identify dosage sensitive genes contributing to 
some DS phenotypes (Baek et al., 2009; Chakrabarti et al., 2010; Lana-Elola et al., 2016; Lana-
Elola, Watson-Scales, Fisher, & Tybulewicz, 2011). The Dp1Tyb mouse model will help to 
identify the contribution of gene dosage from Mmu16 and skeletal deficits associated with DS.  
1.4 Role of DYRK1A/Dyrk1a in Skeletal Anomalies Associated with DS 
Skeletal phenotypes associated with DS and Ts65Dn mice are well known, however little is 
known about the origins of the bone phenotypes (Arron et al., 2006; Blazek, Malik, et al., 2015). 
Dual specificity tyrosine phosphorylation-regulated kinase 1a (DYRK1A), is found in three copies 
in humans with DS and Ts65Dn mice. It has been hypothesized that altered expression of DYRK1A 
contributes to several DS phenotypes including skeletal abnormalities (Blazek, Malik, et al., 2015). 
Transgenic mice that overexpress Dyrk1a have severe appendicular skeletal deficiencies and an 
osteopenic phenotype (Lee et al., 2009). DYRK1A is a known negative regulator of the key pro-
osteoclastic transcription factors NFAT and RCAN1 (Lee et al., 2009). Dyrk1a and Rcan1 
overexpression negatively regulate Nfat transcriptional activity via phosphorylation of NFAT and 
inhibition of calcineurin by RCAN1, respectively (Arron et al., 2006; Lee et al., 2009). 
Phosphorylation of NFAT reduces its nuclear localization and transcriptional activity (Lee et al., 
2009). NFAT has been known to be involved in the differentiation and survival of osteoblasts and 
osteoclasts (Lee et al., 2009). RCAN1 has been known to regulate calcineurin, which inhibits the 
function of NFAT, if overexpressed it can attenuate osteoclast differentiation (Arron et al., 2006).  
DYRK1A is a candidate gene for skeletal abnormalities seen in humans with DS (Abeysekera 
et al., 2016; Blazek, Abeysekera, et al., 2015). Transgenic Ts65Dn, Dyrk1a+/- mice, with only two 
copies of Dyrk1a from conception onward in all tissues, rescued skeletal deficits such as femoral 
BMD, trabecular thickness, number, separation and percent bone volume (Blazek, Abeysekera, et 
al., 2015). Cortical thickness and cross-sectional area were increased to euploid levels in Ts65Dn, 
Dyrk1a+/- (Blazek, Abeysekera, et al., 2015). In addition, Dyrk1a copy number is associated with 
decreases in osteoblast number and activity and an increase osteoclast number, causing an 
imbalance in bone formation and resorption (Blazek, Abeysekera, et al., 2015). Ts65Dn femurs 
exhibit significant decreases in ultimate force, stiffness, and energy of failure when compared to 
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euploid littermates, however, these are rescued to euploid levels when Dyrk1a copy number is 
reduced in Ts65Dn mice (Blazek, Abeysekera, et al., 2015).  
1.5 Skeletal Anatomy 
The skeleton is divided into major structures axial and appendicular. Axial bone refers to 
bones that located on the axis of the body, including the skull and vertebral column and rib cage. 
The appendicular skeleton includes the pelvis, pectoral, and upper and lower extremities. Long 
bones, particularly the femur and humerus, are a part of the appendicular skeleton. Major 
architectural portions of the long bone can be divided into regions called the epiphysis (distal and 
proximal ends), metaphysis (region between epiphysis and diaphysis, contains the growth plate), 
and diaphysis (midshaft, hollow portion that contains the marrow cavity) (Burr & Allen, 2014).  
1.5.1 Microstructure of Bone Organization  
Organization of bone is determined by its function and mineralization. Collagen associates 
into fiber via triple helix conformation that is stabilized by cross-links (Burr & Akkus, 2014; 
Fonseca, Moreira-Goncalves, Coriolano, & Duarte, 2014; Rodan, 1992). These fibrils are then 
arranged into lamellar bone or sheets and can be found in the endocortical or periosteal surface 
and trabeculae (Burr & Akkus, 2014). Primary bone is deposited on a cartilage surface, without 
resorption of old bone. Secondary bone is bone that is deposited after resorption and highly 
organized consisting of osteons (Burr & Akkus, 2014). Primary bone is arranged as either lamellar 
sheets, fibrolamellar, or osteons each having mechanical or physiological properties (Burr & 
Akkus, 2014). Osteons refer to concentric circles that fill vascular channels (Burr & Akkus, 2014; 
Florencio-Silva, Sasso, Sasso-Cerri, Simoes, & Cerri, 2015). These microstructures form a larger 
macrostructure of bone commonly referred to as cortical (compact) and trabecular (spongy or 
cancellous) bone (Burr & Akkus, 2014; Florencio-Silva et al., 2015).  
1.5.2 Macrostructure 
The diaphysis of the long bone and the skull are classified as cortical and function to 
provide protection and support (Burr & Akkus, 2014). Compact bone is made of densely packed 
osteons that fill vascular channels with bone in concentric layers to form a haversian system (Burr 
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& Akkus, 2014; Rodan, 1992). In between the haversian canals are spaces, referred to as lacunae 
where osteocytes are found (Burr & Akkus, 2014; Rodan, 1992). Canaliculi are small channels 
that connect mature osteocytes to one another (Burr & Akkus, 2014).   
Cancellous or spongy bone can be found in the metaphysis of long bones, the vertebrae, 
ribs and illac crests (Burr & Akkus, 2014; Fonseca et al., 2014). It consists of plates and rods of 
bone that are highly interconnected (Burr & Akkus, 2014) and this apparent haphazard 
arrangement provides structural support. The number, size, and organization of trabecular bone 
influences the mechanical strength of the bone (Wallace, 2014b). The interaction of mineralization, 
microstructure and macrostructure define both whole bone and material properties of bone, 
affecting the overall bone quality and resistance to fracture (Wallace, 2014b).   
1.5.3 Background of Bone Biology 
The skeleton is a highly dynamic and multifunctional organ that provides several important 
functions within the body, including mechanical support, protection, mineral homeostasis, and a 
source of hematopoiesis (Burr & Akkus, 2014). Bone is considered a hierarchical material ranging 
from nanostructures to macrostructures (Burr & Akkus, 2014; Wallace, 2014b). At the nanoscale 
level bone is comprised of mineral, collagen, and noncollangeous proteins (Burr & Akkus, 2014). 
These nanoscale materials then form larger composite structures of mature bone consisting of 
cortical bone and trabecular bone each with distinct architecture (Rodan, 1992). Hierarchical 
arrangement of bone allows for it to perform several functions including support, mechanical 
strength, adaption to loads, and repair of damaged skeletal tissue all dependent on the composition 
of the skeleton (Burr & Akkus, 2014).  
The cells that support bone formation and homeostasis are osteoblasts, osteoclasts, and 
osteocytes (Bellido, Plotkin, & Bruzzaniti, 2013; Burr & Akkus, 2014). These cells are responsible 
for creating the lamellar structure of bone to form the macrostructure of bone (Burr & Akkus, 
2014). To fulfill its functions as well as to form the skeleton, bone is continually formed and 
resorbed via osteoblasts and osteoclasts, otherwise known as bone remodeling (Burr & Allen, 2014; 
Florencio-Silva et al., 2015; Rodan, 1992). Bone remodeling consists of resorption followed by 
bone formation at the same location and its serves to renew the skeleton (Burr & Allen, 2014; 
Rodan, 1992). Bone modeling refers to either the formation or resorption of bone at a given surface 
(globally independent) and serves to maintain bone shape and size (Burr & Allen, 2014). Bone 
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homeostasis is often referred to the coupling activity of osteoblasts and osteoclasts in effort to 
maintain skeletal integrity and mineral homeostasis (Burr & Allen, 2014; Rodan, 1998). Bone 
mineralization, structure, and mechanical strength are achieved by the coordination of osteoclastic 
resorption and osteoblastic formation (Rodan, 1998).  The coordination or coupling activity is 
thought to maintain bone balance, meaning equal amount of bone that is resorbed an equal amount 
of bone is formed at a specific location (Burr & Allen, 2014). Normally the balance is slightly 
negative meaning slightly less bone is replaced than is resorbed (Burr & Allen, 2014; Rodan, 1998). 
An imbalance in this process can lead to disease states such as osteoporosis, a net loss in bone 
mass and therefore causes an increase in fracture risk. 
1.5.4 Bone Composition 
The extra cellular matrix of bone consists of mineral, organic polymers, and water (Burr & 
Akkus, 2014; Florencio-Silva et al., 2015). Calcium hydroxyapatite crystal, (Ca10(PO4)6(OH)2) is 
the major mineral found in bone, and makes up about 50-70% of mature bone (Burr & Akkus, 
2014; Florencio-Silva et al., 2015). The organic portion of bone is made of approximately 90% 
type 1 collagen and about 10% is made of noncollagenous proteins (NCPs). Collagen forms fibrils 
that are arranged into lamellar sheets, and then connected by cross-links that influence the 
mechanical properties of the bone (Burr & Akkus, 2014; Burr & Allen, 2014). NCPs play a role 
in the regulation of collagen formation, mineralizing, cell attachment, fibril size and microcrack 
resistance (Burr & Akkus, 2014). The composition of bone can determine its ability to resist 
fracture, commonly referred to as bone quality. Bone quality is determined by architecture and 
geometry, material properties, bone turnover, microdamage, and response to mechanical stimuli 
(Burr & Akkus, 2014; Fonseca et al., 2014).  
1.6 Function of Bone Cells 
The skeleton is a dynamic organ constantly undergoing resorption followed by formation, 
allowing the bone to alter its structure or provide minerals to the rest of the body (Florencio-Silva 
et al., 2015; Fonseca et al., 2014; Robling, Fuchs, & Burr, 2014). Bone growth, modeling and 
remodeling are regulated by spatial and temporal relation between resorption and formation. 
(Bellido et al., 2013; Burr & Allen, 2014; Fonseca et al., 2014; Robling et al., 2014). This process 
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is thought to contribute to mineral homeostasis and mechanical strength (Robling et al., 2014; 
Rodan, 1992).  
1.6.1 Osteoblasts  
Osteoblasts are cuboidal cells and their main function is to synthesize new bone matrix 
(Florencio-Silva et al., 2015; Rodan, 1992, 1998). Osteoblasts are normally found on the surface 
of the bone and form the osteoid that consists of type 1 collagen and other matrix proteins 
(Florencio-Silva et al., 2015; Rodan, 1992, 1998). Mineralization of the newly formed bone matrix 
is accomplished via alkaline phosphatase (ALP) and osteocalcin activity (Florencio-Silva et al., 
2015; Rodan, 1992). As osteoblasts deposit new bone matrix they can become trapped and 
differentiate into osteocytes or become quiescent as bone lining cells (Bonewald, 2011; Florencio-
Silva et al., 2015; Rodan, 1992). Osteoblasts are derived from the mesenchymal stem cell lineage 
(Bellido et al., 2013; Florencio-Silva et al., 2015; Rodan, 1992) and their differentiation is 
regulated by an array of transcription factors and hormonal signaling including BMPs, TGF-B, 
PTH, and Wnt signaling (Bellido et al., 2013; Florencio-Silva et al., 2015). The expression of 
Runx2 and Osterix (Osx) are critical in osteoblast differentiation (Bellido et al., 2013; Florencio-
Silva et al., 2015; Nakashima et al., 2002). Runx2, the master regulator of osteoblast differentiation, 
is required for commitment to the osteoblast lineage and for subsequent Osx expression (Bellido 
et al., 2013; Nakashima et al., 2002; Wysokinski, Pawlowska, & Blasiak, 2015). Changes in 
osteoblast differentiation and/or activity can increase bone mass and reduce fracture risk (Burr & 
Allen, 2014; Fonseca et al., 2014; Rodan, 1998).  
1.6.2 Osteoclasts 
Osteoclasts are large multinucleated cells and are the primary resorptive cells in the bone 
(Florencio-Silva et al., 2015; Rodan, 1992). They are essential for bone remodeling and modeling 
by maintaining homeostasis and reshaping bone in response to mechanical stress (Bellido et al., 
2013; Rodan, 1992). They are derived from the hematopoietic monocyte-macrophage lineage in 
the bone marrow (Bellido et al., 2013; Florencio-Silva et al., 2015). Osteoclast precursors are 
stimulated by M-CSF and Receptor activator of nuclear factor kappa-B ligand (RANKL) which 
are secreted by osteoblasts and osteocytes (Bellido et al., 2013; Florencio-Silva et al., 2015). 
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RANKL is required for the differentiation of mature osteoclasts by promoting fusion with other 
osteoclast precursors, acquisition of biomarkers specific to osteoclasts and stimulation of 
resorption (Bellido et al., 2013; Florencio-Silva et al., 2015). OPG is a decoy receptor of RANKL, 
inhibits osteoclastogenesis, and is mainly produced by osteocytes and osteoblasts (Bellido et al., 
2013; Bonewald, 2011; Florencio-Silva et al., 2015; Ono & Nakashima, 2018). RANKL induces 
the NFATc1 pathway which essential for osteoclastogenesis and its upregulation increases 
osteoclastic resorption (Bellido et al., 2013; Bonewald, 2011; Lee et al., 2009; Ono & Nakashima, 
2018; Zhou et al., 2010). Fusion of osteoclasts is required for maturation and resorptive activity 
and requires at least 3 or more nuclei to characterize active mature osteoclasts (Bellido et al., 2013). 
When osteoclasts are recruited to the bone surface to initiate resorption, they first attach to the 
bone surface and then create a sealing zone to acidify and degrade the bone mineral matrix through 
the action of cathepsin K and matrix metalloproteases (Bellido et al., 2013; Florencio-Silva et al., 
2015). Abnormal increases osteoclast formation and activity can lead to increases in resorption 
that exceed the rate of bone formation (Bellido et al., 2013; Burr & Allen, 2014).  
1.6.3 Osteocytes 
Osteocytes are the major cells found within bone and are the longest lived (Florencio-Silva 
et al., 2015). Osteocytes are mature osteoblasts that were embedded in newly formed osteoid 
(Bonewald, 2011; Florencio-Silva et al., 2015). They are located within the lacunae of the bone 
and have dendrites that extend outwards that connect to other osteocytes (Florencio-Silva et al., 
2015; Rodan, 1992) creating a lacunocanalicular network. Osteocytes are thought to aid in signal 
transduction by sensing mechanical strain and converting it into biochemical signals (Florencio-
Silva et al., 2015; Robling et al., 2014). Detection of shear stress activates osteocytes to release 
paracrine factors between other osteocytes to coordinate the activities of osteoblasts and 
osteoclasts (Bellido et al., 2013; Plotkin & Bivi, 2014b). Response to mechanical stimuli allows 
the bone to adapt to mechanical loads and osteocytes are thought to mediate this response by 
regulation of the remodeling process (Burr & Allen, 2014; Robling et al., 2014; Wallace, 2014b).  
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1.6.4 Bone Formation 
There are two types of bone formation: endochondral and intramembranous ossification 
(Burr & Allen, 2014; Nakashima et al., 2002; Sinha & Zhou, 2013). Endochondral ossification 
starts with the production of a hyaline cartilage template by chondrocytes that later become 
calcified osteoprogenitor cells. Then the cartilaginous template is replaced by mineralized bone 
tissue (Burr & Allen, 2014; Nakashima et al., 2002; Sinha & Zhou, 2013). Long bones such as the 
femur and tibia, and bones found at the base of the skull are formed by endochondral ossification. 
Intramembranous ossification does not require a cartilage template, comprises of flat bones in the 
skull, the mandible and clavicles. Mesenchymal cells condense and differentiate directly into 
osteoblasts to produce bone matrix (Burr & Allen, 2014; Nakashima et al., 2002; Sinha & Zhou, 
2013). The skull, scapula and clavicle are some of the bones formed via intramembranous 
ossification. 
1.6.5 Bone Modeling and Remodeling 
Bone modeling is formation of bone on an already existing bone surface most prominent 
during longitudinal growth and development (Burr & Allen, 2014; Seeman, 2008). Modeling is 
the primary function to increase bone mass and maintain bone size and shape (Burr & Allen, 2014; 
Seeman, 2008). Mechanical strain is the main signal for modeling and activates the recruitment of 
either osteoblast or osteoclasts (Burr & Allen, 2014; Robling et al., 2014; Seeman, 2008). The 
purpose of modeling during growth is to reach skeletal maturity, or peak bone mass, and this 
process declines in adulthood (Burr & Allen, 2014; Seeman, 2008; Seeman & Delmas, 2006). 
Bone turnover is the coordinated activity of osteoclast bone resorption followed by 
osteoblast bone formation at the same skeletal site (Burr & Allen, 2014; Rodan, 1992, 1998). The 
activity between osteoblasts and osteoclasts must be balanced to prevent bone loss or excess bone 
formation (Burr & Allen, 2014; Rodan, 1992, 1998; Seeman, 2008). Remodeling is the process in 
which bone matrix is replaced in response to microdamage or osteocyte apoptosis (Burr & Allen, 
2014; Seeman, 2008). Bone turnover becomes less rapid after epiphyseal plate closure and peak 
mechanical strength is achieved. The activity of remodeling after the growth period gives the bone 
the ability to adapt and respond to mechanical stress (Burr & Allen, 2014; Fonseca et al., 2014; 
Robling et al., 2014; Seeman, 2008). The frequency of remodeling is high during growth to adapt 
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to stresses (Seeman & Delmas, 2006). Factors thought to regulate remodeling include RANKL, 
OPG, IGF-1, TGF-B, hormones, cytokines and Wnt (Burr & Allen, 2014; Plotkin & Bivi, 2014a; 
Rodan, 1992; Seeman, 2008). The rate of turnover is influence by age, genetics, physical activity, 
nutrition and hormonal activity (Burr & Allen, 2014).  
1.7 Fundamentals of Skeletal Biomechanics 
Bone is considered a hierarchical material having various layers of structural organization at 
different scales that perform a variety of functions (Berman, Clauser, Wunderlin, Hammond, & 
Wallace, 2015; Rho, Kuhn-Spearing, & Zioupos, 1998; Wallace, 2014a). To assess the mechanical 
strength of the bone or resistance to fracture, mechanical tests such as three-point bending is 
performed (Cole & van der Meulen, 2011). When a load is applied in a monotonic manner, 
deformation occurs and when that load exceeds the strength of the bone fracture will occur (Cole 
& van der Meulen, 2011; Martin, 2015; Wallace, 2014a). As load or force is used as a function of 
deformation or displacement, the force-displacement curve is produced (Turner & Burr, 1993; 
Wallace, 2014a). The force-displacement curve can be divided into three regions: an initial linear 
(elastic) region, a postyield (plastic) nonlinear region that contains ultimate load, and the failure 
point in which catastrophic failure occurs (Cole & van der Meulen, 2011; Martin, 2015; Wallace, 
2014a). In the elastic region the bone is deformed as the load increases; if the load is removed, the 
bone can return to its original shape (Cole & van der Meulen, 2011; Martin, 2015; Wallace, 2014a). 
The slope of the elastic region is related to structural stiffness (Turner & Burr, 1993; Wallace, 
2014a). If the load increases past the linear region known as the yield point, permanent (plastic) 
deformation will occur and the bone will not return to its original shape if the load is removed 
(Cole & van der Meulen, 2011; Martin, 2015; Wallace, 2014a). The plastic region, which contains 
ultimate force or load, is defined as the structural strength before catastrophic failure (Martin, 2015; 
Wallace, 2014a). Finally the area under the curve is a measure of work, or energy absorbed by the 
bone until fracture occurs (Martin, 2015; Wallace, 2014a).  
Whole bone strength or mechanical properties depend on the geometry, size of the bone, and 
material properties (Cole & van der Meulen, 2011; Wallace, 2014a). Normalizing for shape and 
size, the load displacement curve is converted to stress (force/area) – strain (∆length/initial length) 
and information related to tissue level properties that excludes geometric properties is obtained 
(Cole & van der Meulen, 2011; Wallace, 2014a). The slope of the stress-strain curve is intrinsic 
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stiffness,  modulus, yield stress, ultimate stress, and toughness (area under the curve); measures 
that are similar to the load-displacement curve but only accounting for tissue level material 
properties (Cole & van der Meulen, 2011; Martin, 2015; Wallace, 2014a).   
1.8 OSTERIX/Sp7 as an Osteoblast Transcription Factor and its Role in Bone Growth 
The appendicular and axial skeleton are derived from distinct cell linages from the paraxial 
mesoderm and the lateral plate mesoderm (Rodda & McMahon, 2006). Several lineages that 
contribute to the development of the skeleton, each contribute to generation of the bone matrix 
secreting cell type, the osteoblast (Rodda & McMahon, 2006). OSTERIX/SP7(OSX) is a zinc 
finger family transcriptional factor critical for osteoblast differentiation and endochondral bone 
formation (Chen et al., 2014; Huang & Olsen, 2015). The gene for Osx is highly conserved between 
mice and humans and it is located on Mmu15 and Hsa12, respectively, and there are only 2 exons 
(Zhang, 2012). OSX activation is downstream of RUNX2 and required for osteoblast maturation. 
It is necessary for embryonic skeletal development and postnatal growth (Zhang, 2012). Both 
endochondral and intramembranous ossification require osteoblasts that express OSX (Nakashima 
et al., 2002; Rodda & McMahon, 2006).   
Osx1-GFP::Cre (Osx-Cre), a BAC transgenic mouse line expressing a GFP::Cre fusion 
protein from the regulatory sequence of Osx, was generated to direct gene deletion in the osteoblast 
lineage (Rodda & McMahon, 2006). The Cre activity is normally confined to the osteogenic 
perichondrium, periosteum and osteoblast lineage cells within the marrow cavity (Rodda & 
McMahon, 2006). OSX is required for osteoblast differentiation, function, and bone formation and 
can be used to understand skeletogenesis at specific stages of bone development (Huang & Olsen, 
2015). 
1.9 Thesis Hypotheses 
1.9.1 Hypothesis 1: Sexual Dimorphism in the Dp1Tyb Mouse Model of DS 
Gene dosage influences skeletal abnormalities and sexual dimorphism contributes to 
differences seen between humans (male and female) with DS. Thus, we examined male and female 
control and Dp1Tyb animals. Our hypothesis was that Dp1Tyb male mice would exhibit similar 
phenotypes compared to male individuals with DS, while female mice would display a distinct 
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skeletal phenotype compared to their male littermates. The onset and severity of skeletal deficits, 
such as osteoporosis, are also influenced by age. Hence, we hypothesized that skeletal deficits are 
differentially affected depending on chronological age in Dp1Tyb animals with increasing severity 
in older mice.  
1.9.2 Hypothesis 2: Role of Dyrk1a in Bone Abnormalities in Ts65Dn/Dyrk1afl/+/Osx-Cre+ 
Mice 
Dyrk1a is found in three copies in humans with DS and Ts65Dn animals, and contributes 
to skeletal abnormalities. In trisomic Ts65Dn adolescent mice, Dyrk1a copy number has been 
shown to increase osteoblast number, however osteoclast number is decreased in adult trisomic 
animals (Blazek, Abeysekera, et al., 2015; Fowler et al., 2012). Altered expression of Dyrk1a 
results in skeletal deficits associated with a low bone turnover phenotype, causing deficits in 
skeletal microarchitecture and material properties. We hypothesize that reduction of Dyrk1a to 
two copies in mature osteoblasts in an otherwise trisomic mouse will ameliorate skeletal deficits 
associated with bone formation. An Osx-cre driver was used to genetically return Dyrk1a to normal 
levels in the preosteoblasts and mature osteoblasts of male and female Osx-Cre,Ts65Dn,Dyrk1afl/+ 
mice in order to understand trisomic Dyrk1a’s role in osteoblast differentiation, function, and 
survival.  
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 MATERIALS AND METHODS 
2.1 Experimental Animals 
C57BL/6J.129P2-Dp(16Lipi-Zbtb21)1TybEmcf/Nimr (Dp1Tyb) mice (Lana-Elola et al., 
2016) were bred at the Medical Research Council (MRC) Harwell Institute, UK by crossing to 
C57BL/6J mice. Genotyping was undertaken using custom probes (Transnetyx). Female mice 
were nulliparous. Femurs were isolated from Dp1Tyb and littermate wild-type mice at 6 and 16 
weeks of age. Right femurs were stored in phosphate buffered saline (PBS)-soaked gauze, shipped 
on dry ice and stored at -80º C to be used for microcomputed tomography (µCT) analysis and 
mechanical testing. Left femurs were stored in 70% ethanol and analyzed for dynamic and static 
histomorphometry. From our previous skeletal analyses, we estimated that we would need ten mice 
of each genotype to quantify both trabecular and cortical bone parameters (α = 0.05, 1- β = 0.80 in 
power analyses). Femurs from 6-week-old male (n=10 control, n=10 Dp1Tyb) and female (n=12 
control, n=11 Dp1Tyb); and 16-week-old male (n=13 control, n=12 Dp1Tyb) and female (n=19 
control, n=22 Dp1Tyb) were used. All assessment of femurs was done with investigators blind to 
sample genotype. Histomorphometry was only completed on 16-week-old male and female mice. 
All regulated procedures were carried out with approval from a Local Ethical Review Panel and 
under authority of a Project License granted by the UK Home Office, and in accordance with EU 
Directive 2010/63/EU. 
2.1.1 Breeding Scheme of Ts65Dn,Dyrk1afl/+, Osx-Cre+ Animals 
Female Ts65Dn mice with a floxed Dyrk1a gene (Ts65Dn, Dyrk1afl/+) were bred to Osx1-
GFP::Cre mice+/+ (B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J). Osx1-GFP::Cre (Osx-Cre) mice 
are commonly used to target osteoblasts. They have a tTA and tetracycline responsive element-
controlled GFP/Cre fusion protein under the control of the Osterix (Sp7) promoter. Osx-Cre is 
normally expressed from embryonic development E14.5 and postnatal development (Rodda & 
McMahon, 2006; Wang, Mishina, & Liu, 2015). All mice were generated on a ~50% B6 and 50% 
C3H background to match the background of Ts65Dn mice. Dyrk1a inducible knockdown mice 
(Dyrk1afl/+) were heterozygous for a construct with lox sites, that, with induced Cre expression, 
will splice out exons 5 and 6 eliminating the kinase activity of one copy of Dyrk1a (Fotaki et al., 
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2002; Thompson et al., 2015). We 
have not been able to generate 
Ts65Dn, Dyrk1afl/fl mice due to 
possible lethality of homozygous 
floxed offspring interacting with 
the trisomic genome.  
Osx-Cre mice were bred to 
homozygosity via test cross and 
verification by PCR genotyping, 
and with 25% of the offspring 
containing Cre on both alleles.  In 
Ts65Dn, Dyrk1afl/+ offspring with 
Osx-Cre transgene, active Cre 
recombinase will eliminate one 
functional copy of Dyrk1a in osteoblasts. Treatment with doxycycline can prevent the expression 
of the GFP-Cre protein and recombination of the target gene (Rodda & McMahon, 2006; Wang et 
al., 2015). Expected ratios of the four genotypes are: 1/8 Ts65Dn, Dyrk1afl/+, Osx-Cre+; 1/8 
Euploid, Dyrk1afl/+, Osx-Cre+; 3/8 Ts65Dn control; 3/8 euploid control mice.  
Groups of female mice were generated for testing: 3 copies of Dyrk1a (Ts65Dn,Dyrk1a+/+/+ 
[same as Ts65Dn]) n=42; trisomic mice with 2 active copies of Dyrk1a (Ts65Dn,Dyrk1a+/+/- [same 
as Dyrk1afl/+,Osx-Cre+]) n=24; euploid mice with 2 copies of Dyrk1a (Eu,Dyrk1a+/+) n=10; 
euploid mice with 1 active copy of Dyrk1a (Eu,Dyrk1a+/-[same as Dyrk1afl/+, Osx-Cre+ ) n=7. 
Right femurs were stored in 70% EtOH and used for histomorphometry. Left femurs were stored 
in gauzed soaked PBS and used for microCT analysis and mechanical testing. To test the 
hypothesis that Dyrk1a reduction can improve the overall strength of trisomic bones and 
ameliorate the sexual dimorphism associated with Dyrk1a expression. 
2.2 Genotyping  
All Ts65Dn mice were genotyped using the breakpoint PCR protocol (Reinholdt et al., 2011). 
Ts65Dn mice carry a translocation between chromosomes (Chrs) 16 and 17 (Davisson et al., 1993). 
The translocation chromosome, Mmu1716, is freely segregating. It carries 13.4Mb of the distal 
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Mmu16 fused with the centromere of Mmu17. Primers spanning the translocation breakpoint were 
used to genotype euploid and trisomic mice (Reinholdt et al., 2011).  
The primer sequences were Chr17fwd (GTGGCAAGAGACTCAAATTCAAC) and 
Chr16revs (TGGCTTATTATTATCAGGGCATTT) to amplify a ~275bp product at the 
breakpoint sequence. A positive internal control primer set consisted of IMR8545 
(TGTCTGAAGGGCAATGACTG) and IMR8546 (GCTGATCCGTGGCATCTATT) that yields 
a product around 544bp. The final PCR mix contained MyTaq reaction buffer (1x), MyTaq 
polymerase (2.5U/ul), water, mutant primers (0.5uM), internal positive control (0.4uM), and DNA 
(~100ng/rxn). PCR cycling conditions were for 35 cycles (94°C for 2 minutes and 30 seconds; 
94°C for 15 seconds; 58.5°C for 15 seconds; 72°C for 10 seconds; 72°C for 1 minute). Products 
were run on an 1.5% agarose gel with 4ul of SYBRGold. The size of the PCR products was 
compared to DNA ladder to confirm the presence of the Ts65Dn breakpoint fragment from euploid 
animals.  
Primer sequences for Osx-Cre were 30295 forward 
(GAGAATAGGAACTTCGGAATAGTAAC) and 30296 reverse 
(CCCTGGAAGTGACTAGCATTG) that amplifies a 198bp band. PCR cycling conditions was (2 
minutes at 94°C, 15 seconds at 94°C, 15 seconds at 55°C, 15 seconds at 72°C, 2 minutes at 72°C) 
for 35 cycles with 10 minutes 4°C hold. These primers were changed to forward Osx10 
(CTCTTCATGAGGAGGACCCT) and reverse TGCK (GCCAGGCAGGTGCCTGGACAT) 
with a ~500bp product, PCR conditions (1 minute at 94°C, 30 seconds at 94°C, 30 seconds at 55°C, 
30 seconds at 68°C, 2 minutes at 72°C) for 39 cycles. Internal controls were consistent throughout 
the study and were 25775 forward (AGAGAGCTCCCCTCAATTATGT) and 25776 reverse 
(AGCCACTTCTAGCACAAAGAACT) creating a product about 253bp. Lastly, all Ts65Dn, 
Dyrk1a, Osx-Cre offspring underwent PCR protocol to detect the presence of the loxP sites 
flanking exons 5 and 6 of Dyrk1a (Thompson et al., 2015). The forward primer was 25066 
(TACCTGGAGAAGAGGGCAAG) and the reverse 25067 (GGCATAACTTGCATACAGTGG) 
for 35 cycles (3 minutes at 95°C, 20 seconds at 95°C, 20 seconds at 60°C, 15 seconds at 72°C, 1 
minutes at 72°C). WT animals produced a single band around 503bp, heterozygous animals 
produced amplicons at 503 and 603bp, and homozygous animals produced a single fragment at 
603bp.  
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2.3 Fluorescent Labeling 
Male and female Osx-Cre animals were aged to 6 weeks. Mice were injected 
intraperitoneally at 5 weeks of age with 0.2ml of 1.0% of Calcein green dye. Four days after initial 
injection of Calcein green, mice were injected again. Three days after the second injection mice 
were euthanized and weighed. Right femurs were extracted and used for tissue histomorphometry. 
2.4 Microcomputed Tomography (uCT)  
Femurs were thawed to room temperature and scanned using high-resolution µCT system, 
SkyScan 1172 microCT (SkyScan, Kontich, Belgium) using the following parameters: voltage 
60kV, resolution 12µM, binning mode 2k and filter Al 0.5mm. Calibrations were performed daily 
using two cylindrical hydroxyapatite phantoms (0.25 and 0.75g/cm3 calcium hydroxyapatite). 
Femurs were rewrapped in PBS soaked gauze and stored at -80ºC until mechanical testing. 
Reconstruction analysis was performed using NRecon and CTan software (Skyscan, Bruker 
microCT, Belgium). Trabecular microarchitecture and cortical geometry were accomplished using 
previously published protocol (Abeysekera et al., 2016; Berman et al., 2015).  
Trabecular analysis was performed on the distal metaphysis with a region of interest (ROI) 
defined as 10% of the total bone length, approximately 1mm proximal to the distal growth plate 
and then extending proximally. The ROI was auto-segmented using custom Matlab (MathWorks, 
Inc. Natick, MA) code (Berman et al., 2015). Measurements from trabecular architecture (bone 
volume fraction [BV/TV], trabecular thickness, number and separation), bone mineral density 
(BMD) and tissue mineral density (TMD) were obtained using CTAn. 
Cortical analysis was performed at a standard site 60% of the total bone length away from the 
distal growth plate. Seven transverse slices were generated from the standard site and cortical 
geometric properties were obtained from using a custom Matlab code.  
2.5 Mechanical Testing 
The mechanical properties of the femur were determined by 3-point bending using a 
mechanical testing machine (TA ElectroForce 3200; Eden Prairie, MN, USA). The femurs were 
thawed to room temperature and tested in the anterior-posterior direction with the posterior surface 
in compression (7 mm support span). The load was applied to the midpoint of each bone. The 
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femur was preloaded using 0.5N to establish contact with the bone and then monotonically tested 
to failure at a displacement rate of 0.025 mm/s while fully hydrated. Load and deflection were 
recorded, from which structural strength (yield and ultimate), stiffness (slope of the linear portion 
of the force versus displacement curve), and deformation (yield deformation, postyield 
deformation and total deformation) were determined (Wallace, Golcuk, Morris, & Kohn, 2009; 
Wallace et al., 2006). Distance from the proximal end of the femur to the location of the fracture 
initiation was measured using calipers. Seven transverse slices were obtained from µCT at the 
location of fracture and calculated geometric properties (bending moment of inertia and distance 
from the centroid to the tensile surface of the bone). Along with the deflection data, the moment 
of inertia and distance from the centroid to the tensile surface of the bone in tension derived were 
used to map load-displacement into stress vs. strain curves using standard equations derived from 
Euler-Bernoulli beam theory to estimate tissue level properties (Wallace et al., 2009). The 
mechanical strength, stiffness, and work/toughness were determined from the force vs. 
displacement and stress vs. strain curve.  
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In these equations, F is the force, d is the displacement, a is the distance from the support to 
the inner loading point (4 mm), and L is the span between the outer supports (7 mm). The yield 
point was calculated using the 0.2% offset method based on the stress-strain curve. The modulus 
of elasticity was calculated as the slope of the linear portion of the stress-strain curve. 
2.6 Histology  
Femurs were removed and placed in 70% ethanol (EtOH) and stored at room temperature 
until ready for use. The femur was separated from at the midshaft and the proximal and distal 
femurs were processed, cut and sectioned as described (Blazek et al., 2011). Briefly, right femurs 
were dehydrated in graded levels of EtOH, cleared in xylene and embedded in methyl methacrylate. 
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For dynamic histology, the midshaft of the femur was sectioned into 500µm transverse sections 
and ground to 40µm and then mounted using Eukitt to enhance viewing of fluorescent label. One 
section was read using a D-FL Epi-Fluorescence attachment on a Nikon Eclipse 80i DIC 
microscope, and images were taken using a Nikon DS-Fi1 digital sight camera.  
2.6.1 Dynamic Histomorphometry 
Mineralizing surface/bone surface (MS/BS) was assessed by measuring the double label 
surface (dL.S), single label surface (sL.S), and total bone surface (BS) using BioQuant software 
(R & M Biometrics, Nashville, TN; MS/BS = (dL.S.+ 0.5*sL.S)/BS). Mineral apposition rate 
(MAR) was determined by measuring the average interlabel width between two fluorochrome 
labels using the Bioquant software, divided by the number of days between label administration. 
MS/BS and MAR were used to quantify bone formation rate (BFR). BFR = MS/BS * MAR * 365; 
µm3/µm2/year. Based on the measurements obtained from dynamic labeling, some mice had to be 
removed from analysis, for the periosteal surface 16-week-old male (n=9 wild-type, n=7 Dp1Tyb) 
and female (n=9 wild-type, n=9 Dp1Tyb) were used. For the endocortical surface, 16-week-old 
male (n=10 wild-type, n=8 trisomic) and female (n=11 wild-type, n=10 trisomic) were used. 
2.6.2 Static Histomorphometry 
Briefly, sections of the distal femur were deplasticsized in acetone and stained for the osteoid 
using the Von Kossa-MacNeal’s tetrachrome protocol or osteoclasts using TRAP staining. Osteoid 
surface/bone surface (OS/BS) was quantified using Bioquant software. For osteoclasts, osteoclast 
surface to bone surface (OcS/BS), and osteoclast number per 1mm tissue (Oc#/BS) were quantified 
using Bioquant software. 16-week-old male (n=13 control, n=10 Dp1Tyb) and female (n=11 
control, n=12 Dp1Tyb) were used. 
2.7 Statistical Analysis   
MicroCT and mechanical testing data were analyzed using a custom Matlab code (Berman 
et al., 2015). For microCT, mechanical testing, and histomorphometry data, normality and 
homogeneity were assessed for each phenotype and any violations were transformed to achieve 
normality. To control for the analysis of multiple dependent variables, separate MANOVAs (Wilks’ 
 
 
39 
Lambda, IBM SPSS version 26) were performed on the 6- and 16-week-old mice for trabecular (4 
parameters), cortical (14 parameters) and mechanical (16 parameters) data. If the MANOVA for a 
given age and bone type yielded significant main or interactive effects of genotype and/or sex, 
follow-up 2-way factorial ANOVAs were performed on each individual parameter to identify 
which of the individual parameters expressed the main (or interactive) effects that were significant 
in the MANOVA. If the MANOVA yielded no significant effects, no additional follow-up analyses 
were performed. Effect sizes were obtained from the SPSS calculations of partial eta squared in 
each ANOVA. For each parameter with a significant interaction, posthoc analyses (Tukey’s 
multiple comparisons test) determined differences between groups.  
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 RESULTS 
INTERACTION OF SEXUAL DIMORPHISM AND GENE DOSAGE 
IMBALANCE IN SKELETAL DEFICITS ASSOCIATED WITH DOWN 
SYNDROME 
3.1 Preface 
The results for this study have been recently published in Bone. I was the first author for this 
article. I contributed to the study design, microCT analysis, mechanical testing and histological 
analysis. I was also responsible for writing, editing, and proofing the manuscript, and making 
necessary changes requested by reviewers.  
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3.1.1 Preliminary Skeletal Analyses 
Preliminary analyses on mice at 14 weeks showed an effect of both sex (p<0.001) and 
genotype (trisomy or extra gene dosage) on the length from nose to base of tail (p=0.001) (Dp1Tyb 
male = 89.84 (SE±0.86) mm; control male = 93.12 (0.94) mm; Dp1Tyb female = 85.24 (1.15) mm; 
control female = 88.56 (0.41) mm; n=10 for all samples). Male and control mice overall showed a 
longer body at 14 weeks. The length of the femur was greater in wild-type mice as compared to 
Dp1Tyb mice at 14 weeks (p<0.001) (Dp1Tyb male = 14.78 (0.20) mm; control male = 15.72 
(0.20) mm; Dp1Tyb female = 14.76 (0.22); control female = 15.40 (0.18); n=10 for all samples).  
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3.2 Interaction of Sex and Genotype in Dp1Tyb Mice Alters BV/TV during Skeletal 
Maturation  
The interaction of sex (male vs. female) and genotype (three copy vs. normal copy number) 
was important in percent bone volume (bone volume/tissue volume or BV/TV) at both 6 and 16 
weeks of age. At 6 weeks of age during longitudinal bone growth, BV/TV was reduced in male 
Dp1Tyb, female Dp1Tyb and female control animals as compared to male control animals (Fig. 
1A). At 16 weeks of age, a time of skeletal maturity, BV/TV continued to be reduced in male 
Dp1Tyb, female Dp1Tyb and female control animals as compared to male control animals. 
Additionally, female Dp1Tyb mice had reduced BV/TV as compared to male Dp1Tyb mice (Fig. 
1A). BV/TV increased in male mice from 6 to 16 weeks of age (p<0.001), but female mice 
exhibited a loss in BV/TV during the same time period (p=0.025). Similar data were observed for 
BMD in the trabecular compartment at both 6 and 16 weeks.  
3.3 Interaction Between Sex and Genotype Affects Trabecular Microarchitecture in Male 
and Female Dp1Tyb and Wild-Type mice 
 Measurements of other trabecular skeletal parameters provide insight into the interaction 
between sex and genotype. Trabecular number (Tb.N) is increased in male wild-type mice 
compared to female Dp1Tyb and wild-type mice at 6 and 16 weeks (Fig. 1B) and trabecular 
thickness (Tb.Th) is greater in male wild-type mice than male and female Dp1Tyb and wild-type 
mice at both 6 and 16 weeks (Fig. 1C). Trabecular separation (Tb.Sp) is greater in female than 
male mice at 16 weeks (Fig. 1D). In male mice, Tb.N increased (p=0.013) and Tb.Sp decreased 
(p=0.034) from 6 to 16 weeks for both genotypes. Tb.Th showed an age × genotype interaction 
(p=0.021) in male mice. When only female mice were analyzed together at 6 and 16 weeks, Tb.N 
decreased and Tb.Th and Tb.Sp increased (p<0.001 for all).  
3.4 Cortical Bone Parameters Exhibit an Interaction Between Sex and Genotype in 
Dp1Tyb and Control mice, with most Interactive Effects at 16 Weeks 
Six week-old control male and female mice had a greater total cross-sectional area (total 
CSA) in the cortical bone than Dp1Tyb male and female mice (Fig. 2A). Total CSA increased 
from 6 to 16 weeks in male (p<0.001) but not female (p=0.61) mice. At 16 weeks of age, total 
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CSA is larger in control male than all other mice, male Dp1Tyb as compared to female Dp1Tyb 
mice, and female control as compared to female Dp1Tyb mice. 
The sexual dimorphism and effects of trisomic gene dosage in total CSA were further 
understood by examining other cortical parameters. At 6 weeks of age, all control as compared 
Dp1Tyb mice together had a larger marrow area, cortical area, cortical thickness, periosteal bone 
surface (Ps.BS), endosteal bone surface (Es.BS), Imax, and Imin. Male as compared to female 
mice overall exhibited greater cortical area, Imax and Imin (Table 1 & Fig. 2). In addition to a 
reduction in cortical structural parameters, Dp1Tyb mice exhibited lower tissue mineral density 
(TMD) compared to their wild-type counterparts.  
At 16 weeks of age, male control mice had larger total CSA, cortical area, Ps.BS, Es.BS and 
Imax compared to all other mice, with male mice as a group with higher parameters compared to 
female mice, and female Dp1Tyb mice having the lowest measurements (Table 1 & Fig. 2). 
Marrow area and Imin are greater in male control than all other mice, and female control are greater 
than female Dp1Tyb mice for these same parameters. Female mice as a group had reduced cortical 
thickness compared to male mice. These data suggest that the smaller total CSA in male Dp1Tyb 
as compared to control mice at 6 and 16 weeks is due to reduced Ps.BS, Es.BS, cortical thickness 
and marrow area at both ages. In female mice, total CSA appears unchanged and cortical area and 
thickness is increased from 6 to 16 weeks with decreases in Es.BS and marrow area. 
3.5 Mechanical Bone Parameters Exhibit a Sexual Dimorphism in Extrinsic Bone 
Properties in Dp1Tyb and Control Mice. 
The interactive effect and main effect of genotype were significant when all mechanical 
parameters at 6 weeks were analyzed together by MANOVA, and the sex effect was marginal 
(p=0.100). Interactive, sex, and genotype effects were all significant at 16 weeks when mechanical 
parameters were analyzed together by MANOVA. At 6 weeks of age in the mechanical properties 
of extrinsic bone (properties based on bone mass and geometry), the only sex × genotype 
interaction was for stiffness, with male euploid mice having greater stiffness than all other mice. 
Control as compared to Dp1Tyb mice at 6 weeks exhibited higher yield force (bone undergoes 
permanent deformation), ultimate force (measuring general strength of bone), postyield work 
(energy absorbed after permanent deformation), and total work (total energy absorbed by the bone 
during bending). Male as compared to female 6-week-old mice also showed a higher ultimate force. 
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(Table 2 and Fig. 3). At 16 weeks of age, the only sex × genotype interaction for extrinsic bone 
properties was for ultimate force, with control males greater than all other mice and Dp1Tyb males 
greater than Dp1Tyb females. Control as compared to Dp1Tyb mice at 16 weeks of age had a 
higher postyield displacement, stiffness, postyield work, and total work; and Dp1Tyb as compared 
to control mice displayed higher values of displacement to yield and work to yield. At 16 weeks 
of age, males as compared to females had higher measurements for stiffness, postyield work, and 
total work (Table 3 and Fig. 3).  
3.6 Dp1Tyb and Female Mice Appear to have Improved Intrinsic Bone Properties  
At 6 weeks of age there were no effects in the intrinsic properties (material properties 
independent of size and shape) of bone in Dp1Tyb as compared to control or male as compared to 
female mice. At 16 weeks, control males had a lower modulus (stiffness of material) than all other 
mice (sex × genotype interaction), and both female and male Dp1Tyb mice had a higher modulus 
than their control littermates (Table 3 and Fig 3). Also at 16 weeks, bone from Dp1Tyb as 
compared to control mice displayed a higher yield stress (normalized force to size and shape of 
bone), ultimate stress, and resilience. Control as compared to Dp1Tyb mice had a higher total 
strain. Female mice had marginally increased yield stress as compared to male mice.  
3.7 Histomorphometric Analysis of Cellular Properties show Sex Effects in Dp1Tyb and 
Control Mice 
To understand more about the cellular properties of the femur at 16 weeks when sex and 
genotypic dimorphisms in intrinsic and extrinsic properties are observed, we analyzed dynamic 
properties in both cortical (femur midshaft) and trabecular (distal femur) bone. In addition, but not 
related to mechanical assessment, we analyzed static properties in the trabecular bone of 16-week-
old male and female Dp1Tyb and control littermate mice. In cortical bone on the periosteal surface, 
male as compared to female mice showed increased MS/BS (p<0.001, percentage of bone 
undergoing active formation, and an estimate of osteoblast activity), BFR (p=0.04, measure of the 
total rate of new bone formation on the surface being mineralized) and MAR (p=0.04, osteoblast 
vigor, the rate at which osteoblasts lay down new bone matrix or osteoid) (Fig. 4A-C). On the 
endocortical surface, male control as compared to all other mice had a smaller MS/BS (p=0.008) 
 
 
44 
(sex × genotype interaction). Male control as compared to all female mice had a smaller BFR 
(p=0.04) (sex × genotype interaction) (Fig. 4D-F).  
 In the trabecular bone, there was an increase in female control as compared to male control 
bone in MS/BS (p=0.02) and BFR (p=0.02) (sex × genotype interaction) (Fig. 5A-C). Bone from 
female as compared to male mice exhibited a higher trabecular MAR (p=0.02) at 16 weeks of age 
(Fig. 5C). Osteoid surface per bone surface (OS/BS) (p=0.04) and OS/BS percentage (p<0.001) 
were also greater in trabecular bone of female as compared to male mice. Male Dp1Tyb mice had 
a lower osteoclast number on the bone surface (Oc#/BS) as compared to all other mice at 16 weeks 
of age (sex × genotype interaction, p=0.02) (Fig 5D) as measured by Tartrate-resistant acid 
phosphatase (TRAP) labeled multinucleated osteoclasts. Additionally, the percentage of bone 
surface covered by osteoclasts (OcS/BS) was significantly reduced in male as compared to female 
(p=0.004) and control as compared to Dp1Tyb (p=0.0001) mice (Fig 5D).  
When comparing only mice of the same sex, we observed a marginally increased trabecular 
osteoblast activity and vigor in 16-week-old male Dp1Tyb male as compared to control mice 
(MS/BS: p=0.04, and BFR p=0.10, 2 tailed T test). In 16-week-old female mice, there was a 
suggestive decrease in Dp1Tyb as compared to control mice in trabecular MS/BS and BFR (p=0.11 
and p=0.09, 2 tailed T test). There was reduced trabecular bone osteoclast surface and number in 
the distal femur of male Dp1Tyb as compared to control littermates at 16 weeks of age (p<0.001, 
1 tailed T test). In female mice at 16 weeks there was a slight reduction in percent osteoclast 
number in Dp1Tyb as compared to control animals (p=0.06, 2 tailed T test) and no difference in 
osteoclast surface between Dp1Tyb and control mice in trabecular bone. No difference was found 
between male Dp1Tyb and control mice in periosteal cortical MS/BS, MAR, or BFR; there was 
an increase in Dp1Tyb endosteal MS/BS (p=0.02, 2 tailed T test) but no differences in endosteal 
MAR or BFR. There were no significant differences in female periosteal MS/BS, MAR or BFR.  
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EFFECTS OF OSTEOBLAST SPECIFIC DYRK1A REDUCTION IN 
TS65DN FEMALE MICE 
3.7.1 Trabecular Skeletal Deficits in Down syndrome Female Animals  
Six week old euploid female mice with two copies of functional Dyrk1a (Eu, Dyrk1a+/+) had 
a greater percent bone volume, more Tb.N, and reduced Tb.Sp (Fig 6) compared to both trisomic 
mice with three copies of Dyrk1a (Ts65Dn,Dyrk1a+/+/+) and trisomic mice with two copies of 
Dyrk1a in the osteoblasts (Ts65Dn, Dyrk1a+/+/-). There were no significant differences seen in 
Tb.Th. Euploid mice with one copy of Dyrk1a did not show any significant trabecular deficits 
compared to either euploid or trisomic mice (Fig 6). These data suggest that significant differences 
are detected between euploid and trisomic mice and indicating trisomy alters trabecular 
microarchitecture. Reduced copy number of Dyrk1a in osteoblasts did not improve trabecular 
deficits at this age in female mice (Fig 6). Ts65Dn,Dyrk1a+/+/+ and Ts65Dn,Dyrk1a+/+/- had a 
significantly reduced BMD compared to euploid, suggesting alteration in mineralization in the 
trabecular compartment (Fig 9).  
3.7.2 Alteration of Cortical Geometry in Female Ts65Dn Mice 
Female Ts65Dn, Dyrk1a+/+/+ mice at 6 weeks of age exhibited significant perturbations in 
cortical parameters as compared to Eu, Dyrk1a+/+mice (Fig 7). Total CSA was reduced in both 
trisomic groups as compared to euploid controls (Fig 7A). In addition, trisomic mice had a smaller 
cortical area, marrow area (Fig 7B&C) and thickness (Fig 8A). Both the periosteal (Ps.BS) and 
endocortical bone surfaces (Es.BS) were reduced in Ts65Dn, Dyrk1a+/+/+ and only Ps.BS was 
reduced in Ts65Dn, Dyrk1a+/+/- mice compared to Eu,Dyrk1a+/+ littermates (Fig 8B&C). 
Therefore, female Ts65Dn, Dyrk1a+/+/+ mice exhibited altered cortical geometry compared to 
controls. Imax and TMD were significantly decreased in both trisomic groups (Table 4). 
3.7.3 Extrinsic and Intrinsic Properties in Female Ts65Dn  
Female trisomic mice exhibited few significant differences compared to euploid control 
mice. Ultimate force, postyield and total work were greater in euploid mice compared to both 
trisomic groups (Table 5 and Fig 10). Total strain was reduced in Ts65Dn,Dyrk1a+/+/+ compared 
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to euploid mice (Table 5 and Fig 10). There were no other differences between genotypes in both 
extrinsic and intrinsic properties.  
3.7.4 Postnatal Death of Ts65Dn,Dyrk1afl/+ Male Mice 
It had been observed that very few male mice survived with the Ts65Dn,Dyrk1afl/+,Osx-
cre+ genotype, with an expected ratio of 1/8. Upon further analysis it was shown that 
Ts65Dn,Dyrk1afl/+,Osx-cre+ male mice were not generated as expected. Because of this 
phenomenon male mice were excluded from this study. A total of 44 male mice were born and 
only 2 Ts65Dn,Dyrk1afl/+,Osx-cre+ mice survived until 6 weeks of age (Table 6). We 
hypothesized that the Ts65Dn,Dyrk1afl/+,Osx-cre+ genotype was postnatally lethal to male mice. 
All deceased mice were genotyped to validate this hypothesis. There was a total of 44 mice that 
died between what ages postnatal day zero (P0) and P42, with 28 males and 15 females that 
perished. In addition, 30 mice out of all 44 who expired postnally, did not possess Osx-cre 
recombinase. Only 2 male mice out of all 44 mice had the Ts65Dn,Dyrk1afl/+,Osx-cre+ genotype. 
The most common age at death was one day after birth, with 24 out of 44 of the dead animals. 
Ts65Dn,Dyrk1afl/+,Osx-cre+ does not appear to contribute to postnatal death seen in male mice. It 
still remains unclear what is causing the male mice to die. Further investigations into possible 
factors related to the absence of Ts65Dn,Dyrk1afl/+,Osx-cre+ mice amongst the genotypes will be 
explored, including examining embryos to determine if male mice die before birth.  
3.7.5 Confirmation of Cre-mediated Deletion of Dyrk1a in Osteoblasts. 
All mice were genotyped before death and mice that were positive for Osx-cre were 
analyzed to determine if cre-mediated deletion was successful. Dyrk1a is floxed between exons 5 
and 6, after cre-mediated deletion exon 4 is then joined with exon 7. Primers were generated to 
identify the Floxed deletion allele spanning the novel sequence between the rejoined exon 4 and 
exon 7. The presence of a 214bp band, confirmed deletion of exons 5 and 6 of Dyrk1a. Extraction 
of osteocyte DNA from the tibia of Osx-cre female mice were analyzed to detect the confirmation 
of cre-mediated deletion, presence of trisomy and Dyrk1afl/+. Preliminary data of 10 Osx-cre+ 
female mice that were genotyped to confirm, via PCR, the presence of a Dyrk1afl/+ allele, trisomy 
and Osx-cre recombinase. 8 out of 10 mice that were positive for Dyrk1afl/+ and Osx-cre+ 
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generated a Floxdel allele, confirming Dyrk1a was reduced in osteoblasts and osteocytes. Also, 
there were no changes from their original genotype. The 2 remaining mice that were negative for 
Dyrk1afl/+ and Osx-cre+, and produced Floxdel product, suggesting a possible change in genotype, 
specifically they were mis-genotyped.  
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 DISCUSSION 
4.1 Interaction of Sexual Dimorphism and Genetic Dosage Imbalance in Dp1Tyb Mouse 
Model 
The novel examination of male and female mice in the Dp1Tyb mouse model of DS during 
typical times of bone accrual and skeletal maturity revealed the effect of both the sex of the mouse 
and the presence/absence of three copies of dosage sensitive genes on skeletal phenotypes 
associated with DS. Here we report the first evidence of sexual dimorphism in skeletal deficits of 
DS model mice that parallels differences between skeletal deficits in humans with DS of different 
sexes. The non-invasive quantification of bone deficits in humans with DS gives insight into some 
parameters, including BMD, but does not provide information on the geometry or composition of 
bone. BMD is a metric used to calculate risk factor for fracture, however, many studies do not 
include geometry, structural and strength indices that also affect fracture incidence (Fowler et al., 
2012; Gonzalez-Aguero, Vicente-Rodriguez, Gomez-Cabello, & Casajus, 2013). Until recently, 
studies of bone in individuals with DS have often been done using small sample sizes that may 
have not been able to detect important changes in bone between males and females with DS during 
various developmental time points. Using mouse models of DS allows for the quantification of 
structural, mechanical and cellular properties during different times of bone development. The data 
obtained show clear age, sexual, and genotypic differences in several measures that recapitulate 
many phenotypes observed in individuals with DS, especially at formative developmental stages. 
 At 6 weeks of age, trabecular parameters including BV/TV, Tb.Th, Tb.N and Tb.Sp are 
adversely affected in both Dp1Tyb and wild-type littermate female mice and are at similar levels 
as Dp1Tyb male mice. Although females have reduced trabecular measures compared to male 
wild-type mice at 6 weeks of age, trisomy does not further reduce those measures. These data 
suggest a protective effect of female sex against trisomic defects during longitudinal bone growth. 
As mice reach the age of skeletal maturity at 16 weeks, BV/TV of female mice has not increased; 
furthermore, Tb.N has decreased and Tb.Th and Tb.Sp have increased in both Dp1Tyb and wild-
type mice. In female mice, the reduction in Tb.N and increase in Tb.Sp may have negatively 
influenced connectivity to the point that even with increased Tb.Th at 16 weeks, skeletal 
measurements are still adversely affected.   
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Male Dp1Tyb present with a reduction of percent bone volume at 6 weeks and is persistent 
until 16 weeks age suggesting that the process of bone formation is negatively activate during 
adolescence (active growth) and sexual maturity. Male control and Dp1Tyb mice develop 
trabecular bone between 6 and 16 weeks consistent with a normal growth pattern, however 
Dp1Tyb mice exhibit structural deficits compared to control mice. 
Female mice gain Tb.Th and Tb.Sp, while theylose Tb.N and BV/TV between 6 and 16 weeks.  
Thus, indicating reduced bone formation or increased resorption across ages. Trabecular deficits 
in female mice appear to be independent of genotype at both 6 and 16 weeks. Taken together, these 
results show that trisomy has little effect on the trabecular microarchitecture of female mice but 
could contribute to a decrease in bone formation or an increase in resorption of trabeculae.  
 At 6 and 16 weeks, Dp1Tyb male and female mice generally have deficits in cortical 
geometry as compared to their wild-type counterparts. The total CSA increased in male but not 
female mice from 6 to 16 weeks of age. Measures of cortical bone in male and female Dp1Tyb 
mice are similar at 6 weeks. Female mice as a group do not have increases of total CSA across 
ages, but exhibit decreases in marrow area and an increase in cortical area. Dynamic 
histomorphometry of the femoral midshaft suggests this increase is largely due to increased 
activity of osteoblasts on the endocortical surface in female mice suggesting endocortical 
contraction. Changes in cortical geometry for control and Dp1Tyb mice in the cortical bone 
follows a normal pattern of skeletal growth, with three copies of genes enhancing deficits in female 
mice.  
4.1.1 Dyrk1a Genetic Dosage in Osteoblast in Female Ts65Dn,Dyrk1a Mice in Trabecular 
and Cortical Microarchitecture 
At 6 weeks of age, trisomic female mice have detrimental trabecular deficits compared to 
euploid mice. There is a distinct phenotype between genotypes that is absent in Dp1Tyb female 
animals. Both trisomic animals, Ts65Dn, Dyrk1a+/+/+ and Ts65Dn, Dyrk1a+/+/- have attenuated 
BV/TV and Tb.N with increased Tb.Sp. Therefore, female trisomic mice either exhibited an 
impairment in bone formation or increased resorption of trabeculae. Decreased copy number of 
Dyrk1a in osteoblasts in no way altered or improved trabecular deficits observed in trisomic 
animals and did not adversely affect euploid mice with only one functional copy of Dyrk1a. 
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Female trisomic mice at 6 weeks of age, in Ts65Dn, Dyrk1a+/+/+ and Ts65Dn, Dyrk1a+/+/- 
exhibited decreased Total CSA, and cortical area emphasizing reduce bone size and confirmed by 
a reduction in cortical thickness and TMD. These alterations suggest possible deficits either in 
diminished bone accrual or increased resorption via cortical thinning. Furthermore, female 
trisomic and knockdown animals have a smaller Ps.BS, and only trisomic animals exhibit a 
reduction in Es.BS highlighting differences in bone maintenance between groups. Ts65Dn, 
Dyrk1a+/+/- animals did not have a reduced marrow area compared to euploid controls, possibly 
indicating alterations in bone accrual or maintenance of the medullary cavity compared to 
Ts65Dn,Dyrk1a+/+/+ animals.  
This is a novel trisomic phenotype seen in Ts65Dn female trisomic mice and is contrary to 
what is observed in Dp1Tyb female animals. Differences in trisomic genetic content and 
background might contribute to specific phenotypes associated to female Dp1Tyb and Ts65Dn, 
Dyrk1a+/+/- and Ts65Dn, Dyrk1a+/+/+ skeletal deficits in femoral architecture. Observed 
differences in skeletal phenotypes between Dp1Tyb and Ts65Dn can contribute to ongoing debate 
concerning the effectiveness of specific mouse models to recapitulate human phenotypes 
associated with DS. Identification of molecular or cellular mechanisms responsible for the etiology 
of disruption of bone homeostasis remains unclear, and the use of appropriate mouse models is 
essential to their discovery. 
4.2 Trabecular and Cortical Phenotype Comparison of Dp1Tyb, Female Ts65Dn and 
Other DS Model Mice 
 Bone deficits associated with DS were first identified in Ts65Dn male mice (Blazek et al., 
2011). A comparison between these and previously published results reveals similar direction and 
magnitude in trabecular, cortical and mechanical deficits in mice that are at dosage imbalance for 
genes homologous to Hsa21 (Blazek, Abeysekera, et al., 2015; Blazek et al., 2011). Previous 
studies of 6, 12, 16 week, and 24 month old male mice found no significant differences in 
trabecular thickness (Tb.Th) between Ts65Dn and euploid mice, though these values were near a 
p<0.05 significance level (Blazek et al., 2011; Fowler et al., 2012). Tb.Th was significantly 
different between Ts65Dn and control mice at 6 weeks of age and were corrected in 
Ts65Dn,Dyrk1a+/- mice in a subsequent study (Blazek, Abeysekera, et al., 2015). The differences 
in Tb.Th between Dp1Tyb and wild-type mice seem to confirm the dissimilarities in the later study. 
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The data presented confirm that the Dp1Tyb DS mouse model is an effective model for skeletal 
deficits in male and female DS model mice. 
Ts65Dn, Dyrk1a+/+/- mice had a spatiotemporal reduction of Dyrk1a copy number in 
osteoblast cells expressing Osx. Ts65Dn, Dyrk1a+/+/- and Ts65Dn, Dyrk1a+/+/+ mice each 
demonstrated skeletal deficiencies in T.Sp, Tb.N, and BV/TV; similar to observed phenotypes 
between male Ts65Dn mice and Dp1Tyb compared to euploid controls (Blazek, Abeysekera, et 
al., 2015). In contrast, Ts65Dn, Dyrk1a+/+/-(affecting only mature osteoblasts) did not display any 
correction of trabecular or cortical defects as seen in male Ts65Dn, Dyrk1a+/-(global deletion of 
Dyrk1a) from Blazek et al, 2015a (Blazek, Abeysekera, et al., 2015). Additionally, Ts65Dn, 
Dyrk1a+/+/- and Ts65Dn, Dyrk1a+/+/+ showed more significant differences between euploid 
controls, which was not observed between female Dp1Tyb and control animals both at 6 weeks of 
age. Differences between Dp1Tyb and Ts65Dn skeletal anomalies could arise from genetic 
background and gene dosage, which is discussed later in this manuscript.  
Male and female Ts1Rhr mice, containing 33 triplicated genes, at 3 and 16 weeks have 
been examined for bone deficits associated with DS (Olson & Mohan, 2011). At 3 weeks (a 
developmental age prior to where we identified differences in BV/TV at 6 weeks in Dp1Tyb and 
control littermate female mice), BMD was not statistically different between male or female 
Ts1Rhr or control mice. It may be that BMD is not significant between Ts1Rhr and control male 
mice at this pre-pubertal age. At 16 weeks, in Ts1Rhr and littermate control mice, areal BMD was 
not significantly different in the femur, but was decreased in the tibia and increased in the spine. 
Our analyses of Dp1Tyb and littermate mice found significantly different trabecular BMD between 
both male and female mice at 16 weeks of age. Further studies, including microCT, were not 
performed on the bones of Ts1Rhr and control littermate mice, and given the analyses included 
herein, we hypothesize that other structural and mechanical bone abnormalities exist between 
Ts1Rhr and control mice. Conversely, the reduction in genes at dosage imbalance in Ts1Rhr as 
compared to Dp1Tyb mice could dilute any potential effect from triplicated genes. 
Differences between skeletal abnormalities could also be due to genetic background, number 
and which genes are at dosage imbalance, and origin of the change in genetic dosage. Differences 
in skeletal phenotypes could be due to differences in triplicated gene content or genetic background 
of Ts65Dn (104 genes, ~50% B6 and ~50% C3H) and Dp1Tyb (148 genes, 100% B6) and Ts1Rhr 
(33 genes, 100% B6) mice. Differences in trisomy may also contribute to skeletal differences 
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between mouse models. Ts65Dn has a freely segregating extra chromosome with the telomeric 
end of Mmu16 attached to the centromeric end of Mmu17. This includes ~35 protein-coding genes 
at dosage imbalance from Mmu17 that are not homologous to Hsa21 (Duchon et al., 2011; Gupta 
et al., 2016; Reinholdt et al., 2011). Both Dp1Tyb and Ts1Rhr mice have a duplication of parts of 
the distal end of Mmu16 and do not have a freely segregating trisomic chromosome. All of these 
factors may lead to differences between the DS mouse models that have been used to detect skeletal 
abnormalities associated with DS. We note that as the gene content of Dp1Tyb mice is known, it 
may now be possible to look for the causal genes for bone defects, i.e. those sequences on Hsa21 
that have an effect when present in three copies. 
4.3 Similarities Between Humans with DS and Mouse Models with DS 
It is hypothesized that the osteoporotic phenotype found in individuals with DS is highly 
influenced by limited bone mineral accretion and reduced peak bone mass attainment during 
adolescence (Costa et al., 2018; Tang et al., 2019). In humans the age of total body peak bone mass 
has been estimated to be about 18.8 years in females and 20.5 years in males (Baxter-Jones, 
Faulkner, Forwood, Mirwald, & Bailey, 2011). Individuals with DS attain peak bone mass earlier 
and at lower levels than normal individuals (Costa et al., 2018). Women with DS (as well as normal 
women) have bone mineral accrual later than men, but experience rapid bone loss after the age of 
40 (Tang et al., 2019). Men with DS have a gradual loss of bone after early adulthood, similar to 
men without DS, but the rate of loss is increased in men with DS (Carfi et al., 2017; Tang et al., 
2019). 
Information from the analyses described herein concentrated on skeletal properties during 
bone accrual (6 weeks) until the estimated age of skeletal maturity in mice (16 weeks) (Jilka, 2013). 
There are few studies that have examined DS skeletal deficits in humans during adolescence and 
the time of peak bone accrual, and the results from Dp1Tyb male and female mice may help explain 
previous reports. The lower BMD seen in adolescent males and females with DS analyzed together 
as compared to normal individuals (Kao et al., 1992; Matute-Llorente et al., 2013) compares to the 
genotype effect causing low BV/TV (and BMD) in 6-week Dp1Tyb mice. A study of adolescents 
with DS that found no differences in BMD between males and females (Matute-Llorente et al., 
2017) correlates to the similar BV/TV levels in 6 week old male and female Dp1Tyb mice. At an 
age corresponding to skeletal maturity in individuals with DS, both males and females had a lower 
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BMD (Angelopoulou et al., 1999), with DS females having a lower BMD than DS males in their 
limbs (Baptista et al., 2005); both male and female Dp1Tyb mice had significantly affected bone 
structure at 16 weeks, and trabecular and cortical values were significantly lower in females than 
males at 16 weeks. The data presented herein also demonstrate that male Dp1Tyb mice exhibit 
osteopenic phenotypes earlier than their control counterparts, similar to what has been observed in 
individuals with DS (Carfi et al., 2017; McKelvey et al., 2013) and that osteoporotic phenotypes 
affect males as well as females in early adult stages (Tang et al., 2019).  
4.4 Mechanical Properties of Dp1Tyb Mice 
Bone is hierarchical and alterations in bone composition, architecture, and cellular activity 
can increase or decrease bone strength. Our results suggest changes in cortical geometry possibly 
contributed to differences observed in mechanical properties of Dp1Tyb and WT mice. At 6 weeks 
of age, most of the significant differences between Dp1Tyb and control mice were found in whole 
bone properties. In general, control and male mice at 6 and 16 weeks had stronger bones or greater 
resistance to bending and catastrophic failure compared to their Dp1Tyb counterparts. Genetic 
dosage imbalance could be sufficient to cause alterations in the developing skeleton of male mice 
resulting in reduced strength of femur. 
At 16 weeks enhanced effects on bone tissue, independent of bone size and shape, were 
observed. Female as compared to male mice displayed an increase in yield stress but had 
marginally lower toughness. These changes in material properties of bone in Dp1Tyb mice may 
indicate changes in mineralization of the femur and possibly result in bones that are more prone to 
fracture. Dp1Tyb mice showed an increase in yield properties in both the load-displacement and 
stress-strain curves. Increases in yield properties are related to bone mineral content and post-yield 
properties associated with collagen (Garnero, 2015). Dp1Tyb mice had lower toughness, post yield 
work and total work, suggesting they absorbed less energy prior to fracture and possibly fracture 
sooner than control animals.  
Taken together, these data indicate that there was a strong genotypic effect at 6 weeks in 
extrinsic bone properties but at 16 weeks, sex and especially genotype had non-interactive effects 
on overall bone properties. At 16 weeks of age, additional gene dosage and female sex were 
detrimental to whole bone properties. Additional, Dp1Tyb and female mice at 16 weeks seem to 
have alterations in material bone properties as compared to control and male mice. This is observed 
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especially in the elastic region before the bone becomes permanently deformed, correlating to 
significant changes in mineralization in females.  
4.4.1 Mechanical Properties in Female Ts65Dn, Dyrk1afl/+Osx-Cre Animals 
Unexpectedly, there were not many differences in whole bone properties or material 
properties between female euploid and trisomic mice based on three-point bending analysis. 
Ultimate force was significantly decreased in female trisomic and Ts65Dn,Dyrk1a+/+/- mice, 
indicating there was reduced bone strength compared to euploid animals. Reduction in total work 
was shown also in both trisomic groups compared to euploid mice. Therefore, trisomic animals 
absorb less energy meaning a reduced ability to deal with damage and overall strength. Lastly, 
total strain was reduced in trisomic animals highlighting reduced ductility. In contrast, 
Ts65Dn,Dyrk1a+/+/+ and Ts65Dn,Dyrk1a+/+/- mice had  reduced TMD in cortical bone. There were 
no other differences between genotypes in both extrinsic and intrinsic properties. These findings 
suggest there might be alterations in the material properties in female trisomic mice that contribute 
to resistance to deformation.  
4.5 Cellular Deficits in Mouse Models of DS 
Quantification of cellular composition in trabecular and cortical bone in 6-week-old male 
Ts65Dn as compared to control mice showed reduced osteoblast number and/or activity coupled 
with increased osteoclast activity caused the DS like skeletal deficits at that age (Blazek, 
Abeysekera, et al., 2015; Blazek et al., 2011). A low bone turnover hypothesis was proposed for 
the deficits skeletal deficits seen in 12-week-old male Ts65Dn mice because of decreased 
osteoclast and osteoblast activity found on proximal tibia and femur as compared to euploid mice 
at this age (Fowler et al., 2012). In 16-week-old male mice, we observed increased osteoblast 
activity and reduced osteoclast number and activity in the trabecular compartment of Dp1Tyb as 
compared to control mice. In female mice of the same age, there was a decrease in Dp1Tyb 
osteoblast activity. These results indicate that osteoblast and osteoclast activity was different in 
16-week-old male Dp1Tyb mice than previously reported osteoblast and osteoclast activity in 
Ts65Dn mice at 6 and 12 weeks (Blazek, Abeysekera, et al., 2015; Fowler et al., 2012). Only a 
slight increase in osteoblast activity on the periosteal surface of male Dp1Tyb cortical bone was 
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observed. These data support the notion that male mice are more active in forming bone on the 
periosteal surface while female and trisomic mice are more active in forming bone on the 
endocortical surface at 16 weeks of age. Therefore, sex, gene dosage, bone location and age are all 
important in the cellular components Dp1Tyb as compared to control mice. Furthermore, the 
cellular mechanisms leading to bone deficits associated with DS may be distinct at different points 
in development.  
These data demonstrate fundamental differences in skeletal development between Dp1Tyb 
and wild-type mice. For the first time, they also indicate clear sexual dimorphisms in the 
development of DS mouse model bone and illustrate time-dependent nature of developmental 
differences in the DS-associated skeletal deficits. Similarities between the abnormalities in humans 
with DS and Dp1Tyb mice suggest that skeletal defects result from conserved mechanisms. Sexual 
dimorphisms, gene dosage, age and bone compartments are all influential in causing alterations in 
developmental properties that lead to the unique skeletal differences caused by trisomy. These 
results will help to better understand how trisomy affects individuals with DS and determine which 
measures may prevent adverse skeletal phenotypes. Additional research is needed to determine 
when sex-specific skeletal abnormalities develop, how interactions between trisomy and sex 
influence specific skeletal alterations, and the influence of sex and trisomy on the cellular 
mechanisms related to these changes in bone development.  
4.5.1 Cre-mediated Deletion of One Functional Copy Number of Dyrk1a 
PCR was performed to detect confirmation of their prior genotype for Dyrk1afl/+, trisomy 
and Osx-cre.  Each mouse was compared to original genotype to detect any changes and the 
Floxdel allele. Female Osx-cre+ mice that contain at least one floxed allele have exhibited a 
Floxdel positive band. This suggests that Dyrk1a copy number has been reduced under the Osx 
promoter. However, based on PCR analysis of DNA obtained from female tibiae, has shown the 
Dyrk1afl/+ allele is present in majority of animals except two out of a total of 10. It is possible that 
other cells are present in the sample besides osteoblasts and osteocytes, or that there was an 
incomplete deletion of the floxed Dyrk1a allele. Further analysis of remaining female Osx-cre+ 
animals is needed to determine efficiency of Cre-mediated deletion of Dyrk1a in osteoblasts and 
osteocytes.  
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4.6 Future Direction 
Dp1Tyb analysis of bone deficits provided the establishment of differences in skeletal 
deficits between male and female mice. We observed little to no significant differences between 
control female and Dp1Tyb female trabecular architecture and cortical geometry at 6 weeks of 
age. This might suggest a protective effect of female compared to males in the onset of skeletal 
abnormalities. Additional investigations into different ages of DS mice could elucidate possible 
developmental timepoints related to the onset of bone deficits. These protective effects could be 
the result of differential expression of trisomic genes, bone turnover markers or hormonal levels. 
Measurements of each of these possible culprits could identify possible differences between males 
and females and the contribution of Ts21 in the onset of skeletal anomalies.  
Dyrk1a has been shown to improve skeletal deficits in several studies, emphasizing its role 
in skeletal development. Previous studies reduced copy number of Dyrk1a globally, whereas in 
this study genetic dosage was reduced only in OSX expressing osteoblasts and mature osteocytes. 
There was little to no benefit seen in female Ts65Dn, Dyrk1a+/+/- animals in both microarchitecture 
and biomechanical properties in female animals. Investigating cell types other than osteoblasts that 
might contribute to skeletal deficits in Ts65Dn, Dyrk1a+/+/- female mice could reveal novel 
mechanisms related to bone accrual, mineralization and homeostasis. Observing skeletal deficits 
in male Ts65Dn, Dyrk1a+/+/- and Ts65Dn, Dyrk1a+/+/+ mice could identify a possible sexual 
dimorphism in Ts65Dn mice and uncover differences in skeletal development and maintenance 
between genotypes.  
DYRK1A has been shown to play a complex role in osteoclast number and increased 
expression of DYRK1A could affect osteoclastogenesis. Reducing DYRK1A in osteoclasts could 
rescue the perturbations in the regulation of osteoclastogenesis, maturation or survival. It has been 
shown that DYRK1A has interactions with other osteoclastic factors including NFATc, Akt, and 
Erk. NFATc is a pro-osteoclastic factor that is negatively regulated by DYRK1A which could 
result in decreased osteoclastogenesis (Arron et al., 2006; Lee et al., 2009). Akt and Erk have been 
shown to play a role in osteoclast differentiation and resorptive activity (Abekhoukh et al., 2013; 
He et al., 2011; Moon et al., 2012). DYRK1A overexpression may negatively regulate skeletal 
development and homeostasis via osteoclastic pathways as opposed through alterations in 
osteoblast activity and differentiation.      
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Global reduction of Dyrk1arescued skeletal deficits seen in Ts65Dn animals as seen in our 
previous study (Blazek, Abeysekera, et al., 2015). This correction of the skeletal phenotype was 
not seen in trisomic Ts65Dn mice with reduced copy of Dyrk1a in osteoblasts under the Osx 
promoter. Therefore, abnormal skeletal phenotypes associated with DYRK1A overexpression may 
not be specific to osteoblasts and does not account for origin of all skeletal anomalies seen in DS. 
It is hypothesized that global reduction of Dyrk1a affected multiple cell types during all stages of 
development. Regulation skeletal development and maintenance are controlled by various 
cytokines, growth factors cell-cell communication and interactions with extracellular matrices. 
Moreover, reduction of Dyrk1ain other cell types, besides just osteoblasts, could be responsible 
for the amelioration of skeletal abnormalities. Therefore, it could be suggested that Dyrk1a alters 
the balance between bone resorption and formation leading to osteopenic phenotypes seen in 
Ts65Dn animals. Identification of other molecular targets associated with Dyrk1aexpression could 
highlight novel developmental pathways associated with skeletal growth, development and 
homeostasis. Future investigations into the cellular or molecular mechanisms that contribute the 
bone phenotype are needed to elucidate specific contributions to the origin of skeletal 
abnormalities.  
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APPENDIX A. DP1TYB INTERACTION OF SEXUAL DIMORPHISM AND 
DOSAGE SENSITIVE GENES IN SKELETAL DEFICITS ASSOCIATED 
WITH DOWN SYNDROME 
 
Figure 1 - Trabecular measures on Dp1Tyb and littermate control femurs at 6 and 16 weeks (mean +/- 
SEM). MANOVAs on the combined four trabecular parameters,  performed separately for the 6- and 16-
week data, respectively, indicated significant sex × genotype interactive effects (p=0.001, p=0.001), along 
with significant main effects of sex (p<0.001, p<0.001) and genotype (p<0.001, p=0.003). The individual 
parameters are  depicted in the four panels: (A) Percent bone volume (BV/TV); 6 weeks: sex × genotype 
interaction: p=0.044, [ηp2=0.103]; genotypic effect: p=0.001, [ηp2=0.275], and sex effect: p<0.001, 
[ηp2=0.426]; 16 weeks: sex × genotype interaction: p=0.001, [ηp2=0.164]; genotypic effect: p=0.069, 
[ηp2=0.056], and sex effect: p<0.001, ηp2=0.785. (B) Trabecular number (Tb.N): 6 weeks: sex × genotype 
interaction: p<.001, [ηp2=0.268]; genotypic effect: p=0.097, [ηp2=.071], and sex effect: p=0.003, 
[ηp2=0.209]; 16 weeks: sex × genotype interaction: p=0.009, [ηp2=.112]; genotypic effect: p=0.345, 
[ηp2=0.015], and sex effect: p<0.001, ηp2=0.779. (C) Trabecular thickness (Tb.Th): 6 weeks: sex × 
genotype interaction: p<0.001, [ηp2=0.283]; genotypic effect: p<0.001, [ηp2=0.413], and sex effect: 
p<0.001, [ηp2=0.446]; 16 weeks: sex × genotype interaction: p=0.015, [ηp2=0.097]; genotypic effect: 
p=0.021, [ηp2=0.089], and sex effect: p<0.001, [ηp2=0.420]. (D) Trabecular separation (Tb.Sp): 6 weeks: 
sex × genotype interaction: p=0.174, [ηp2=0.048]; genotypic effect: p=0.431, [ηp2=0.016], and sex effect: 
p=0.063, [ηp2=0.088]; 16 weeks: sex × genotype interaction: p=0.098, [ηp2=0.046]; genotypic effect: 
p=0.669, [ηp2=0.003], and sex effect: p<0.001, [ηp2=0.736]. Male control (n=10 6 wk; n=13 16 wk); Male 
Dp1Tyb; n=10 6 wk; n=11 16 wk); Female control (n=12 6 wk; n=22 16 wk); Female Dp1Tyb (n=10 6 wk; 
n=16 16 wk). Significant differences and interactions for individual parameters are as determined by 
ANOVA and the p value is followed by partial eta squared [ηp2] as a measure of effect size. Similarities 
and differences between individual groups are determined from Tukey’s multiple comparisons post hoc 
tests; values with the same superscript letter are not significantly different. Letters a,b,c,d are used for 
comparisons of 6 week old animals; letters e,f,g,h are used for comparisons of 16 week old animals. 
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Figure 2 - Cortical measures on Dp1Tyb and control femurs at 6 and 16 weeks (mean +/- SEM). MANOVAs 
on the combined 16 cortical parameters, performed separately for the 6- and 16-week cortical data, 
respectively, indicated significant main effects of sex (p=0.003, p<0.01) and genotype (p<0.001, p<0.001). 
The interaction between sex and genotype was significant at 16 weeks p= p<0.001) but not 6 weeks (p=.236). 
Four of the 16 individual parameters showing significant sex × genotype interactions at 16 weeks are 
depicted in the four panels: (A) Cortical total cross-sectional area (CSA): 6 weeks: sex × genotype 
interaction: p=0.024, [ηp2=0.127]; genotypic effect: p<0.001, [ηp2=0.689], and sex effect: p=0.014, 
[ηp2=0.149]; 16 weeks: sex × genotype interaction: p=0.001, [ηp2=0.177]; genotypic effect: p<0.001, 
[ηp2=0.613], and sex effect: p<0.001, [ηp2=0.574]. (B) Periosteal bone surface (Ps.BS): 6 weeks: sex × 
genotype interaction: p=0.070, [ηp2=0.084]; genotypic effect: p<0.001, [ηp2=0.619], and sex effect: 
p=0.060, [ηp2=0.090]; 16 weeks: sex × genotype interaction: p=0.007, [ηp2=.118]; genotypic effect: 
p<0.001, [ηp2=0.590], and sex effect: p<0.001, [ηp2=0.624]. (C) Endocortical bone surface (Es.BS): 6 
weeks: sex × genotype interaction: p=0.343, [ηp2=0.024]; genotypic effect: p<0.001, [ηp2=0.396], and sex 
effect: p=0.319, [ηp2=0.026]; 16 weeks: sex × genotype interaction: p=0.013, [ηp2=0.101]; genotypic 
effect: p<0.001, [ηp2=0.590], and sex effect: p<0.001, [ηp2=0.635]. (D) Marrow area: 6 weeks: sex × 
genotype interaction: p=0.157, [ηp2=0.052]; genotypic effect: p<0.001, [ηp2=0.430], and sex effect: 
p=0.238, [ηp2=0.036]; 16 weeks: sex × genotype interaction: p=0.002, [ηp2=0.157]; genotypic effect: 
p<0.001, [ηp2=0.607], and sex effect: p<0.001, [ηp2=0.467] in Dp1Tyb and control male and female mice 
at 6 and 16 weeks. Significant differences and interactions for individual parameters are as determined by 
ANOVA and the p value is followed by partial eta squared [ηp2] as a measure of effect size. Similarities 
and differences between individual groups are determined from Tukey’s multiple comparisons post hoc 
tests; values with the same superscript letter are not significantly different. Letters a,b,c,d are used for 
comparisons of 6 week old animals; letters e,f,g,h are used for comparisons of 16 week old animals.  
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Figure 3 - Schematic representation of mechanical testing curves (data represented by mean ± SEM). A and 
B) Representations of force-displacement curves at the structural level. C and D) Representations of stress-
strain curves at the tissue level. S, is related to the stiffness or modulus of the femur. Y, the yield point 
represents elastic behavior, indicating the bone’s resistance to permanent deformation, past this point, U is 
the plastic region or permanent deformation where the bone has sustained permanent damage. 
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Figure 4 - Dynamic bone labeling measures of the cortical region of Dp1Tyb and control femurs at 16 
weeks of age (data represented by mean ± SEM). (A) Periosteal mineralizing surface/bone surface (MS/BS), 
(B) Periosteal mineral apposition rate (MAR), (C) Periosteal bone formation rate (BFR), (D) Endocortical 
MS/BS, (E) Endocortical MAR, (F) Endocortical BFR. In (B) and (C), there were no measurable effects in 
female control MAR and BFR (9 samples in each group). Similarities and differences between individual 
groups are determined from Tukey’s multiple comparisons post hoc tests; values with the same superscript 
letter are not significantly different. Letters a,b,c,d are used for comparisons of 6 week old animals; letters 
e,f,g,h are used for comparisons of 16 week old animals. 
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Figure 5- Dynamic bone labeling quantification of the trabecular region of Dp1Tyb and control femurs at 
16 weeks of age (data represented by mean ± SEM). (A) Trabecular mineralizing surface/bone surface 
(MS/BS), (B) Trabecular mineral apposition rate (BFR), (C) Trabecular bone formation rate (MAR), (D) 
Osteoclast number/bone surface (OC#/BS), (E) Osteoclast surface/bone surface. Similarities and 
differences between individual groups are determined from Tukey’s multiple comparisons post hoc tests; 
values with the same superscript letter are not significantly different. Letters a,b,c,d are used for 
comparisons of 6 week old animals; letters e,f,g,h are used for comparisons of 16 week old animals. 
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Table 1: Cortical Architecture and Geometry of Dp1Tyb and Control Male and Female Mice at 6 and 16 
Weeks 
 
Values are averages (SEM). Similarities and differences between individual groups as determined from Tukey’s 
multiple comparisons post hoc tests; values with the same superscript letter are not significantly different. Letters 
a,b,c,d are used for comparisons of 6 week old animals; letters e,f,g,h are used for comparisons of 16 week old animals. 
Data without letters within a single row are not significantly different from each other. Subject effects are p values 
and partial eta squared (ηp2) in brackets. 
 
 
 
Male 
Control 
6 Weeks 
Male 
Dp1Tyb 
6 Weeks 
Female 
Control 
6 Weeks 
Female 
Dp1Tyb 
6 Weeks 
Between 
subjects 
effects 
Interaction 
Between 
subjects 
effects 
Genotype 
Between 
subjects 
effects  
Sex 
  n=10 n=10 n=12 n=10    
Cortical Area 
(mm2) 
0.82 
(0.03)a 
0.58 
(0.02)b 
0.71 
(0.03)c 
0.56 
(0.02)b 
p=0.091  
[ηp2=0.074] 
p<0.001  
[ηp2=0.566] 
p=0.026  
[ηp2=0.124] 
Cortical 
Thickness (mm) 
0.19 
(0.005)a 
0.15 
(0.003)b 
0.17 
(0.008)a,b 
0.15 
(0.007)b 
p=0.270  
[ηp2=0.032] 
p<0.001  
[ηp2=0.367] 
p=0.139  
[ηp2=0.057] 
Imax (mm4) 0.27 (0.01)a 
0.16 
(0.01)b 
0.22 
(0.01)c 
0.15 
(0.01)b 
p=0.075 
[ηp2=0.081] 
p<0.001  
[ηp2=0.585] 
p=0.019  
[ηp2=0.137]  
Imin (mm4) 0.15 (0.01)a 
0.08 
(0.004)b 
0.12 
(0.005)c 
0.08 
(0.003)b 
p=0.004  
[ηp2=0.202] 
p<0.001  
[ηp2=0.740] 
p=0.001  
[ηp2=0.253] 
TMD (g/cm3 HA) 1.05 (0.01)a 
0.99 
(0.01)b 
1.05 
(0.02)a 
1.01 
(0.02)a,b 
p=0.655  
[ηp2=0.005] 
p=0.001  
[ηp2=0.253] 
p=0.592  
[ηp2=0.008] 
  
Male  
Control 
 16 
Weeks 
Male 
  Dp1Tyb 
16 Weeks 
Female 
Control  
16 Weeks 
Female 
 Dp1Tyb  
16 Weeks 
   
  n=13 n=12 n=20 n=22    
Cortical Area 
(mm2) 
1.09 
(0.02)e 
0.92 
(0.02)f 
0.89 
(0.01)f 
0.82 
(0.01)g 
p=0.005  
[ηp2=0.130] 
p<0.001  
[ηp2=0.476] 
p<0.001  
[ηp2=0.585] 
Cortical 
Thickness (mm) 
0.24 
(0.003)e 
0.24 
(0.004)e 
0.22 
(0.002)f 
0.22 
(0.002)f 
p=0.184  
[ηp2=0.0.30] 
p=0.136  
[ηp2=0.038] 
p<0.001   
[ηp2=0.341] 
Imax (mm4) 0.43 (0.02)e 
0.29 
(0.02)f 
0.26 
(0.01)f 
0.21 
(0.01)g 
p=0.001  
[ηp2=0.189] 
p<0.001  
[ηp2=0.543] 
p<0.001  
[ηp2=0.681] 
Imin (mm4)e,h 0.20 (0.01)e 
0.12 
(0.005)f,g 
0.13 
(0.004)f 
0.11 
(0.004)g 
p<0.001  
[ηp2=0.241] 
p<0.001  
[ηp2=0.609] 
p<0.001  
[ηp2=0.452] 
TMD (g/cm3 HA) 1.14 (0.02) 
1.14 
(0.03) 
1.15 
(0.02) 
1.17 
(0.02) 
p=0.733  
[ηp2=0.002] 
p=0.889  
[ηp2=0.000] 
p=0.573 
 
[ηp2=0.006] 
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Table 2: Mechanical Testing at 6 weeks 
 
Values are averages (SEM). Similarities and differences between individual groups as determined from Tukey’s 
multiple comparisons post hoc tests; values with the same superscript letter are not significantly different. Data without 
letters within a single row are not significantly different from each other. Subject effects are p values and partial eta 
squared (ηp2) in brackets. 
 
Male 
Control 
6 Week 
Male 
Dp1Tyb 
6 Week 
Female 
Control 
6 Week 
Female 
Dp1Tyb 
6 week 
Between 
subjects 
effects 
Interactio
n 
Between 
subjects 
effects 
Genotype 
Between 
subjects 
effects  
Sex 
 n=10 n=10 n=12 n=10    
Yield 
Force 
(N) 
 
6.53 
(0.68) 
5.26 
(0.52) 
6.92 
(1.08) 
4.95 
(0.54) 
p=0.663  
[ηp2=0.00
5] 
p=0.048  
[ηp2=0.09
9] 
p=0.958  
[ηp2=0.00
0] 
Ultimate 
Force 
(N) 
 
12.90 
(0.71)a 
7.87 
(0.34)b 
10.30 
(0.77)c 
7.51 
(0.51)b 
p=0.083  
[ηp2=0.07
7] 
p<0.001  
[ηp2=0.50
3] 
p=0.024  
[ηp2=0.12
7] 
Displace
ment to 
Yield 
(µm) 
 
104.40 
(10.71) 139.10 (13.51) 
149.08 
(26.28) 
150.0 
(25.78) 
p=0.430 
[ηp2=0.01
6] 
p=0.405  
[ηp2=0.01
8] 
p=0.197  
[ηp2=0.04
3] 
Postyield 
Displace
ment 
(µm) 
 
481.80 
(22.66) 464.70 (38.43) 
487.42 
(32.24) 
664.60 
(176.05) 
p=0.279  
[ηp2=0.03
1] 
p=0.371  
[ηp2=0.02
1] 
p=0.253  
[ηp2=0.03
4] 
Total 
Displace
ment 
(µm) 
 
586.20 
(20.94) 603.80 (36.62) 
636.50 
(26.11) 
814.60 
(171.38) 
p=0.353  
[ηp2=0.02
3] 
p=0.259  
[ηp2=0.03
3] 
p=0.135  
[ηp2=0.05
8] 
Stiffness 
(N/mm) 
 
76.81 
(5.58)a 
43.28 
(2.42)b 
55.26 
(3.36)b 
45.13 
(8.23)b 
p=0.032  
[ηp2=0.11
6] 
p<0.001  
[ηp2=0.31
3] 
p=0.068  
[ηp2=0.08
5]  
Work to 
Yield 
(mJ) 
 
0.40 
(0.07) 
0.44 
(0.09) 
0.79 
(0.26) 
0.49 
(0.14) 
p=0.332  
[ηp2=0.02
5] 
p=0.463  
[ηp2=0.01
4] 
p=0.208  
[ηp2=0.04
1] 
Postyield 
Work 
(mJ) 
 
5.39 
(0.34)a 
3.25 
(0.29)b 
4.31 
(0.37)a,b 
3.55 
(0.47)b 
p=0.072  
[ηp2=0.08
3] 
p<0.001  
[ηp2=0.28
1] 
p=0.306  
[ηp2=0.02
8] 
Total 
Work 
(mJ) 
 
5.79 
(0.35)a 
3.69 
(0.28)b 
5.09 
(0.51)a,b 
4.04 
(0.46)b 
p=0.223 
[ηp2=0.03
9] 
p=0.001  
[ηp2=0.26
7] 
p=0.693  
[ηp2=0.00
4] 
Yield 
Stress 
(MPa) 
 
58.02 
(6.09) 
76.45 
(7.79) 
69.84 
(6.93) 
72.97 
(7.39) 
p=0.289  
[ηp2=0.03
0] 
p=0.138  
[ηp2=0.05
7] 
p=0.561  
[ηp2=0.00
9] 
Ultimate 
Stress 
(MPa) 
 
112.41 
(2.44) 
113.16 
(4.09) 
108.19 
(3.67) 
109.74 
(3.54) 
p=0.911  
[ηp2=0.00
0] 
p=0.746 
[ηp2=0.00
3] 
p=0.286  
[ηp2=0.03
0] 
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Table 3: Mechanical testing at 16 week
 
Values are averages (SEM). Similarities and differences between individual groups as determined from Tukey’s 
multiple comparisons post hoc tests; values with the same superscript letter are not significantly different. Data without 
letters within a single row are not significantly different from each other. Subject effects are p values and partial eta 
squared (ηp2) in brackets 
 
 
Male 
Control 
16 Week 
Male 
Dp1Tyb 
16 Week 
Female 
Control 
16 Week 
Female 
Dp1Tyb 
16 week 
Between 
subjects 
effects 
Interactio
n 
Between 
subjects 
effects 
Genotype 
Between 
subjects 
effects  
Sex 
 n=13 n=12 n=20 n=22 
   
Yield 
Force 
(N) 
11.30 
(0.70) 
11.19 
(0.61) 
9.42 
(0.55) 
11.14 
(0.59) 
p=0.158 
[ηp2=0.03
4] 
p=0.211 
[ηp2=0.02
7] 
p=0.134 
[ηp2=0.03
8] 
Ultimate 
Force 
(N) 
19.34 
(0.58)e 
14.98 
(0.52)f 
13.75 
(0.30)f,g 
12.98 
(0.37)g 
p<0.001 
[ηp2=0.23
1] 
p<0.001 
[ηp2=0.37
9] 
p<0.001 
[ηp2=0.57
2] 
Displace
ment to 
Yield 
(µm) 
123.46 
(7.69)e 
154.82 
(11.22)e,f 
133.18 
(8.41)e 
177.06 
(12.29)f 
p=0.552 
[ηp2=0.00
6] 
p=0.001 
[ηp2=0.18
2] 
p=0.132 
[ηp2=0.03
9] 
Postyield 
Displace
ment 
(µm) 
641.54 
(43.80) 
579.64 
(93.59) 
660.32 
(79.03) 
416.94 
(50.45) 
p=0.233 
[ηp2=0.02
4] 
p=0.047 
[ηp2=0.06
6] 
p=0.343 
[ηp2=0.01
6] 
Total 
Displace
ment 
(µm) 
765.00 
(42.51) 
734.45 
(86.39) 
793.50 
(79.51) 
594.00 
(44.07) 
p=0.252 
[ηp2=0.02
3] 
p=0.121 
[ηp2=0.04
1] 
p=0.447 
[ηp2=0.01
0] 
Stiffness 
(N/mm) 
102.79 
(4.79)e 
82.66 
(2.88)f 
82.45 
(3.92)f 
70.22 
(2.99)f 
p=0.333 
[ηp2=0.01
6] 
p<0.001 
[ηp2=0.21
7] 
p<0.001 
[ηp2=0.22
1] 
Work to 
Yield 
(mJ) 
0.82 
(0.10)e,f 
0.99 
(0.15)e,f 
0.74 
(0.08)e 
1.13 
(0.13)f 
p=0.335 
[ηp2=0.01
6] 
p=0.021 
[ηp2=0.08
8] 
p=0.813 
[ηp2=0.00
1] 
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APPENDIX B. DYRK1A GENETIC DOSAGE IN OSTEOBLAST IN 
FEMALE TS65DN,DYRK1A MICE  
 
Figure 6 – Trabecular measure for six week female animals. Error bars (+/- SD). One-way ANOVA 
performed on trabecular parameters indicated significant effects of genotype. (A) Percent Bone Volume; 
(B) Trabecular Separation; (C) Trabecular Number; (D) Trabecular Thickness. Female Euploid,Dyrk1a+/+ 
(n=42); Trisomic,Dyrk1a+/+/+ (n=24); Trisomic,Dyrk1a+/+/- (n=10); Euploid,Dyrk1a+/- (n=7). Similarities 
and differences between individual groups are determined from Tukey’s multiple comparisons post hoc 
tests. (*, p<0.05; **, p<0.005, ***, p<0.0002, ****, p<0.0001) 
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Figure 7 – Cortical measures on female euploid and trisomic femurs at 6 weeks of age. Error bars (+/- SD). 
One-way ANOVA was used to determine significant differences between genotypes. (A) Total CSA; (B) 
Cortical area; (C) Marrow Area; (D) Section Modulus. Trisomic,Dyrk1a+/+/+ and Trisomic,Dyrk1a+/+/- 
animals had significant deficits in Total CSA, Cortical Area, and Section Modulus. Only 
Trisomic,Dyrk1a+/+/+ exhibited deficits in Marrow Area. . (*, p<0.05; **, p<0.005, ***, p<0.0002, ****, 
p<0.0001) 
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Figure 8 - Cortical measures on female euploid and trisomic femurs at 6 weeks of age. Error bars (+/- SD). 
One-way ANOVA was used to determine significant differences between genotypes. (A) Cortical 
Thickness; (B) Periosteal Bone Surface; (C) Endosteal Bone Surface. Euploid,Dyrk1a+/+ had increased 
Cortical Thickness, Ps.BS, and Es.BS compared to Trisomic,Dyrk1a+/+/+ animals. No differences were 
observed between any other genotypes. (*, p<0.05; **, p<0.005, ***, p<0.0002, ****, p<0.0001) 
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Figure 9 – BMD of female Ts65Dn mice. One-way ANOVA was used to determine significant differences 
between genotypes. Trisomic,Dyrk1a+/+/+ and Dyrk1a+/+/- mice lower BMD compared to euploid controls. 
(*, p<0.05; **, p<0.005, ***, p<0.0002, ****, p<0.0001) 
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Figure 10 - Schematic representation of mechanical testing curves (data represented by mean ± SEM). A 
and B) Representations of force-displacement curves at the structural level. C and D) Representations of 
stress-strain curves at the tissue level. S, is related to the stiffness or modulus of the femur. Y, the yield 
point represents elastic behavior, indicating the bone’s resistance to permanent deformation, past this point, 
U is the plastic region or permanent deformation where the bone has sustained permanent damage. 
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Table 4 - Cortical Architecture and Geometry of 6 week Female Ts65Dn mice 
 
Euploid, 
Dyrk1a +/+ 
(n=42) 
Trisomic, Dyrk1a 
+/+/+ (n=24) 
Trisomic, Dyrk1a 
+/+/- (n=10) 
Euploid, Dyrk1a 
+/- (n=7) 
Imax 
(mm^4) 
0.1797 (0.0062) 0.1521 (0.0095)* 0.1397 (0.0103)* 0.1436 (0.0110) 
Theta max 
(deg) 
59.9787 
(12.3217) 
81.0503 (17.6908) 21.9311 (17.2666) 54.5954 
(31.8023) 
Imin (mm^4) 0.0990 (0.0033) 0.0741 
(0.0039)**** 
0.0757 (0.0061)** 0.0816 (0.0064) 
Theta min 
(deg) 
93.0400 (0.7545) 90.6932 (0.7727) 93.9311 (1.3153) 93.1669 (1.9002) 
AP Width 
(mm) 
1.1921 (0.0105) 1.0983 
(0.0136)**** 
1.1185 (0.0217)* 1.1520 (0.0264) 
ML Width 
(mm) 
1.6340 (0.0151) 1.5765 (0.0291) 1.5392 (0.0289) 1.5634 (0.0281) 
AP/ML 0.7306 (0.0056) 0.7002 (0.0109)* 0.7273 (0.0104) 0.7370 (0.0114) 
Iap (mm^4) 0.1789 (0.0061) 0.1517 (0.0094)* 0.1390 (0.0103)* 0.1430 (0.0110) 
Iml (mm^4) 0.0998 (0.0033) 0.0744 
(0.0040)**** 
0.0763 (0.0061)** 0.0822 (0.0065) 
Medial 
Extreme 
(mm) 
0.8136 (0.0080) 0.7705 (0.0143)* 0.7531 (0.0150)* 0.7751 (0.0148) 
TMD 
(g/cm^3 HA) 
1.0808 (0.0049) 1.0592 (0.0063)* 1.0607 (0.0095) 1.0722 (0.0119) 
Values are averages (SEM). Similarities and differences between individual groups as determined from Tukey’s 
multiple comparisons post hoc tests; values with the asterisks denote significance compared to euploid animals. (*, 
p<0.05; **, p<0.005, ***, p<0.0002, ****, p<0.0001) 
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Table 5 – Mechanical Testing of 6 week female mice 
 
Values are averages (SEM). Similarities and differences between individual groups as determined from Tukey’s 
multiple comparisons post hoc tests; values with the asterisks denote significance compared to euploid animals. (*, 
p<0.05; **, p<0.005, ***, p<0.0002, ****, p<0.0001) 
 
 
Euploid, 
Dyrk1a +/+ 
(n=42) 
Trisomic, 
Dyrk1a +/+/+ 
(n=24) 
Trisomic, 
Dyrk1a +/+/- 
(n=10) 
Euploid, 
Dyrk1a +/- 
(n=7) 
Yield Force (N) 6.4055 (0.3216) 5.4721 (0.5445) 5.2549 (0.4460) 5.0477 
(0.2896) 
Ultimate Force 
(N) 
12.1269 
(0.3626) 
9.6960 
(0.4306)*** 
9.9729 (0.6287)* 10.0440 
(0.6642) 
Displacement to 
Yield (µm) 
101.2621 
(4.5441) 
111.7288 (8.0270) 101.7181 
(3.7311) 
95.8871 
(3.8492) 
Postyield 
Displacement 
(µm) 
893.7143 
(64.9399) 
633.5000 
(62.9873) 
935.2000 
(130.6428) 
906.5714 
(180.0648) 
Total 
Displacment 
(µm) 
994.9764 
(65.6901) 
745.2288 
(58.5828) 
1036.9181 
(131.2504) 
1002.4585 
(182.6172) 
Stiffness 
(N/mm) 
143.0620 
(55.7021) 
160.4556 
(108.7069) 
55.8269 (3.4068) 57.7634 
(3.4224) 
Work to Yield 
(mJ) 
0.3689 (0.0296) 0.3718 (0.0641) 0.2882 (0.0337) 0.2560 
(0.0205) 
Postyield Work 
(mJ) 
7.6203 (0.4818) 4.9159 (0.4266)** 6.3510 (0.6808) 6.1641 
(1.0639) 
Total Work 
(mJ) 
7.9892 (0.4931) 5.2877 (0.4111)** 6.6391 (0.6956) 6.4200 
(1.0807) 
Yield Stress 
(MPa) 
78.3212 
(3.2659) 
84.1241 (6.3764) 78.7097 (5.9132) 72.3590 
(2.7426) 
Ultimate Stress 
(MPa) 
149.4028 
(2.4714) 
152.4522 (3.9217) 149.2933 
(5.7450) 
143.6495 
(6.2807) 
Strain to Yield 
(µe) 
27456.2989 
(1270.3358) 
28901.1096 
(2278.7009) 
25495.0868 
(931.8943) 
24762.7929 
(1057.0592) 
Total Strain 
(µe) 
270627.4809 
(18203.2581) 
191300.3102 
(15719.7649)* 
255988.7176 
(29761.2341) 
258922.9442 
(47307.3855) 
Modulus (GPa) 7.2620 (3.1469) 9.6710 (6.5047) 3.3507 (0.1593) 3.2000 
(0.1023) 
Resilience 
(MPa) 
1.2195 (0.0911) 1.4581 (0.2151) 1.0792 (0.1196) 0.9494 
(0.0657) 
Toughness 
(MPa) 
26.8858 
(1.5688) 
21.7338 (1.5571) 25.3643 (2.8536) 23.6593 
(3.6110) 
Failure Force 
(N) 
6.8442 (0.5397) 7.3028 (0.5929) 5.3142 (0.9842) 5.6381 
(0.9422) 
Ultimate 
Displacement 
(µm) 
364.5478 
(7.5229) 
399.0205 
(12.5666) 
359.4181 
(12.0304) 
367.0299 
(22.6065) 
Failure Stress 
(MPa) 
83.7562 
(5.9275) 
113.9926 
(7.5441)* 
76.4849 
(11.2289) 
80.1114 
(12.8767)* 
Ultimate Strain 
(µe) 
98970.1673 
(2387.2733) 
102398.7124 
(3636.3700) 
90449.9640 
(4232.6065) 
95276.4840 
(7082.4633) 
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Table 6 – Postnatal Death of Ts65Dn  
Age at 
Death 
Sex Ts 3 copies Ts 2 copies Eu 2 copies Eu 1 copy  Total 
Aborted Male 4   2    6 
Female 3   1    4 
1 Day Male 6   7 1  9 
Female 4   6    10 
2 Days Male   1 2 1  4 
Female           
14-36 days Male 2 1 1    4 
Female     2    2 
Totals    19 2 21 2 44 
Values are the total number mice that have perished separated by their copy number of Dyrk1a. A total of 2 trisomic 
males with reduced copy number of Dyrk1a died before P42.  
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